WO2012106995A1 - Rorgammat inhibitors - Google Patents

Rorgammat inhibitors Download PDF

Info

Publication number
WO2012106995A1
WO2012106995A1 PCT/CN2012/071017 CN2012071017W WO2012106995A1 WO 2012106995 A1 WO2012106995 A1 WO 2012106995A1 CN 2012071017 W CN2012071017 W CN 2012071017W WO 2012106995 A1 WO2012106995 A1 WO 2012106995A1
Authority
WO
WIPO (PCT)
Prior art keywords
indazol
chloro
trifluoromethyl
benzoyl
fluoro
Prior art date
Application number
PCT/CN2012/071017
Other languages
French (fr)
Inventor
Willem Frederik Johan Karstens
Mario van der STELT
Jos CALS
Rita Corte Real Goncalves AZEVEDO
Kenneth Jay BARR
Hongjun Zhang
Richard Thomas Beresis
Dongshan Zhang
Xiaobang DUAN
Original Assignee
Merck Sharp & Dohme Corp.
N.V. Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2012214029A priority Critical patent/AU2012214029A1/en
Application filed by Merck Sharp & Dohme Corp., N.V. Organon filed Critical Merck Sharp & Dohme Corp.
Priority to EP12744370.3A priority patent/EP2683693B1/en
Priority to JP2013552823A priority patent/JP5934721B2/en
Priority to CN201280018025.3A priority patent/CN103748076A/en
Priority to KR1020137023663A priority patent/KR20140044791A/en
Priority to US13/983,818 priority patent/US9095583B2/en
Priority to MX2013009149A priority patent/MX2013009149A/en
Priority to RU2013141528/04A priority patent/RU2013141528A/en
Priority to CA2828059A priority patent/CA2828059A1/en
Priority to BR112013020352A priority patent/BR112013020352A2/en
Publication of WO2012106995A1 publication Critical patent/WO2012106995A1/en
Priority to US14/752,195 priority patent/US9603838B2/en
Priority to US15/463,371 priority patent/US9884043B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • T helper cells Upon activation by antigen-presenting cells naive T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Thl and Th2 subtypes.
  • cytokine secreting effector T cells such as Thl and Th2 subtypes.
  • Thl7 Upon activation by antigen-presenting cells naive T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Thl and Th2 subtypes.
  • This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17/F, IL-21 and IL-22, and is named Thl7 (Miossec et al, New Eng. J. Med. 2361 : 888-898, 2009).
  • Thl and Th2 effector cells express Tbet and GATA3, respectively.
  • a Thymocyte/T cell specific variant of Retinoic Acid Receptor-related Orphan Receptor (ROR), RORgammaT is highly expressed in Thl7 cells (He et al., Immunity 9: 797-806, 1998).
  • RORgammaT belongs to the nuclear hormone receptor superfamily (Hirose et al., Biochem. Biophys. Res. Comm. 205: 1976-1983, 1994). RORgammaT is a truncated form of
  • RORgamma lacking the first N-terminal 21 amino acids and is, in contrast to RORgamma which is expressed in multiple tissues (heart, brain, kidney, lung, liver and muscle), exclusively expressed in cells of the lymphoid lineage and embryonic lymphoid tissue inducers (Sun et al., Science 288: 2369-2372, 2000; Eberl et al., Nat Immunol. 5: 64-73, 2004).
  • RORgammaT was shown to play a crucial role in non-Thl7 lymphoid cells.
  • RORgammaT was critically important in innate lymphoid cells expressing Thyl, SCA-1 and IL-23R proteins. Genetic disruption of RORgamma in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development (Buonocore et al., Nature 464: 1371-1375, 2010).
  • RORgammaT was shown to play a crucial role in other non-Thl7 cells, such as mast cells (Hueber et al., J Immunol. 184: 3336-3340, 2010).
  • RORgammaT has been identified as a key mediator in the pathogenesis of several diseases (Louten et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009; Annuziato et al., Nat. Rev. Rheumatol. 5: 325-331, 2009). This was confirmed using several disease models
  • autoimmune diseases Genetic ablation of the RORgamma gene in mice prevented the development of experimental autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and colitis (Ivanov et al., Cell 126: 1121-33, 2006; Buonocore et al, Nature 464: 1371-1375, 2010).
  • EAE experimental autoimmune encephalomyelitis
  • colitis Ivanov et al., Cell 126: 1121-33, 2006; Buonocore et al, Nature 464: 1371-1375, 2010.
  • RORgammaT is expected to have a beneficial effect on autoimmune diseases, such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and asthma (Annunziato et al., Nat. Rev. Immunol. 5: 325-331, 2009; Louten et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009). Inhibition of RORgammaT may also be beneficial in other diseases, which are characterized by increased levels of Thl7 cells and/or elevated levels of Thl7 hallmark cytokines such as IL-17, IL-22 and IL-23.
  • autoimmune diseases such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and asthma (Annunziato et al., Nat. Rev. Immunol. 5: 325-3
  • Examples of such diseases are Kawasaki Disease (Jia et al., Clin. Exp. Immunol. 162: 131-137, 2010) and Hashimoto's thyroiditis (Figueroa-Vega et al., J Clin. Endocrinol. Metab. 95: 953-62, 2010).
  • Another example includes infectious diseases, such as, but not limited to, mucosal leishmaniasis (Boaventura et al., Eur. J. Immunol. 40: 2830-2836, 2010). In each of the above examples the inhibition may be enhanced by simultaneous inhibition of RORalpha.
  • agonists include T0901317 and SR1078 (Wang et al, ACS Chem. Biol. 5: 1029-1034, 2010).
  • antagonist have been reported such as 7-oxygenated sterols (Wang et al., J Biol. Chem. 285: 5013-5025, 2009) and compounds described in EP2181710 Al .
  • psoriasis One exemplary immue disorder in need of better therapy is psoriasis.
  • Various therapeutics have been developed in an attempt to treat psoriasis.
  • the present invention provides compounds which inhibit RORgammaT, their use for the treatment of RORgammaT-mediated diseases or conditions, in particular autoimmune diseases and inflammatory diseases, as well as pharmaceutical compositions comprising such compounds and pharmaceutical carriers.
  • the present invention provides a compound according to Formula I
  • X is C(O), SO or S0 2 ,
  • Y is CH or N
  • n 0, 1, 2, 3 or 4;
  • a -A are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A 4 -A 7 can be simultaneously N;
  • R 1 is (i) (C 3 -7)cycloalkyl or (C 3 -5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(0)-, (Ci_
  • R 2 is C(0)OH, 5-tetrazoylyl, HOC(CF 3 ) 2 , C(0)OH(Ci.io)alkyl, (Ci.
  • R 3 is hydrogen, halogen, cyano, nitro, hydroxy, (Cl-3)alkylC(0)0-, (Ci -4 )alkyl, or (Ci_ 4)alkoxy, wherein (Ci -4 )alkyl and (Ci_4)alkoxy are optionally substituted with one or more halogens;
  • R 4 -R 7 independently are H, halogen, amino, cyano, hydroxy, (Ci -3 )alkoxy, (Ci -4 )alkyl, (C 0- io)alkyl)aminocarbonyl, (di)(Ci-6)alkylaminocarbonyl or amino(Ci -4 )alkyl, wherein (Ci_ 3 )alkoxy, (Ci -4 )alkyl, (Co-io)alkyl)aminocarbonyl, (di)(Ci.6)alkylaminocarbonyl and amino(Ci.
  • 4 )alkyl are optionally substituted with one or more halogen, hydroxyl or (Ci -3 )alkoxy; or a group having the , optionally substituted with one or more of the following: (Ci-io)alkyl, halogen, amino, cyano, hydroxy, (Ci -3 )alkoxy, and wherein m is 1, 2, 3, or 4.
  • This invention also provides a compound according to Formula la
  • X represents C(O), SO or S0 2 ,
  • Y is CH or N
  • a -A' are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A 4 -A 7 can be simultaneously N;
  • R 1 is (C 3- 7)cycloalkyl or (C 3- 5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H 2 NC(0)-, or (Ci -3 )alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci -4 )alkyl or (Ci -3 )alkoxy, all optionally substituted with one or more halogens or;
  • R 1 is (C 2 -9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(0)-, or (Ci -3 )alkoxycarbonyl, (di)(Ci.
  • R 1 is (C 6 -i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(0)-, or (Ci -3 )alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci_ 4 )alkyl or (Ci -3 )alkoxy, all optionally substituted with one or more halogens;
  • R 2 is C(0)OH, 5-tetrazoylyl, or HOC(CF 3 ) 2 ;
  • R 3 is independently selected from hydrogen, halogen, cyano, nitro or (Ci -4 )alkyl, optionally substituted with one or more halogens;
  • R 4 -R 7 independently are H, halogen, amino, cyano, hydroxy, (Ci -3 )alkoxy, (Ci -4 )alkyl, optionally substituted with one or more halogens.
  • a 4 , A 5 , A 6 , A 7 are selected from the group consisting of: (i) CR 4 , CR 5 , CR 6 , CR 7 ; (ii) N, CR 5 , CR 6 , CR 7 ; (iii) CR 4 , N, CR 6 , CR 7 ; (iv) CR 4 , CR 5 , N, CR 7 ; (v) CR 4 , CR 5 , CR 6 , N; (vi) N, N, CR 6 ,CR 7 ; (vii) CR 4 , N, N, CR 7 ; (viii) CR 4 , CR 5 , N, N; (ix) N, CR 5 , N, CR 7 ; (x) CR 4 , N, CR 6 , N; and (xi) N, CR 5 , CR 6 , N.
  • a 4 , A 5 , A 6 , A 7 are selected from the group consisting of: (i) CR 4 , CR 5 , CR 6 , CR 7 ; (ii) N, CR 5 , CR 6 , CR 7 ; and (iii) CR 4 , N, CR 6 , CR 7 .
  • a 4 , A 5 , A 6 , A 7 is (i) CR 4 , CR 5 , CR 6 , CR 7 , or (ii) N, CR 5 , CR 6 , CR 7 ; and Y is N.
  • X is C(O) or S0 2 ;
  • R 1 is (i) (C 3- 7)cycloalkyl or (C 3- 5)heterocycloalkyl, both optionally substituted with one or more groups selected from (Ci -4 )alkyl or halogen; (ii) (C 2- 9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (Ci -4 )alkyl; or (iii) (C 6 -i 4 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl, (Ci -3 )alkoxy, wherein (Ci -3 )alkoxycarbonyl, (Ci_ 4 )alkyl and (Ci -3 )alkoxy are optionally substituted with one or more halogens.
  • R 1 is (i) (C 3- 7)cycloalkyl or (C
  • R 1 is (C 2- 9)heteroaryl or (C 6 -i4)aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl or (C ⁇ . 3 )alkoxy, wherein (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl and (Ci -3 )alkoxy are optionally
  • Rl is (C 6 -i 4 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, or (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl or (Ci -3 )alkoxy, all optionally substituted with one or more halogen.
  • R 1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci_
  • R 1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl or (Ci -3 )alkoxy, wherein (Ci -3 )alkoxycarbonyl, (Ci -4 )alkyl and (Ci -3 )alkoxy are optionally substituted with one or more halogens.
  • a tenth subset of the invention relates to compounds according to Formula I and la wherein Y is N.
  • X is C(O) or S0 2
  • R is selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(
  • x is 0, 1, 2, 3, 4 or 5; and A 4 -A 7 , R J -R 3 , Y and n are defined as set forth hereinabove for Formula I.
  • a 4 -A 7 , R 3 , X and n are defined as set forth hereinabove for Formula I.
  • la, lb, Ic, Id, and le are compounds wherein
  • R 4 is selected from H, halogen, amino, and optionally substituted with one or more halogen;
  • R 5 is H
  • R 6 is selected from H, dimethylaminocarbonyl, -CH2NH2, cyano, onally substituted with one or more halogen, hydroxyl,
  • R7 is selected from H and halogen.
  • a still further embodiment of the compounds of Formula I, la, lb, Ic, Id, and le are compounds wherein one of R 4 , R 5 and R 7 is other than hydrogen.
  • the invention also relates to those compounds wherein all specific definitions for A 1 through A 4 , R 1 through R 8 , X, Y, n and x and all substituent groups in the various aspects of the inventions defined here above occur in any combination within the definition of the compound of Formula I.
  • Non-limiting examples of the compunds of the present invention include:
  • alkyl refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond having the specified number of carbon atoms.
  • an alkyl group contains, for example, from 1 to 6 carbon atoms (Ci- C 6 alkyl) or from 1 to 3 carbon atoms (C 1 -C3 alkyl).
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl.
  • an alkyl group is linear. In another embodiment, an alkyl group is branched.
  • alkyl includes both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms; for example, “C 1-6 alkyl” (or “Ci-C 6 alkyl”) includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • Alkylene refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments; for example, the term “A-C 4 alkylene-B” represents, for example, A-CH 2 - CH 2 -CH 2 -CH 2 -B, A-CH 2 -CH 2 -CH(CH 3 )-CH 2 -B, A-CH 2 -CH(CH 2 CH 3 )-B, A-CH 2 - C(CH 3 )(CH 3 )-B, and the like.
  • Alkoxy represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; for example “Ci-Ce alkoxy” includes -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -0(CH 2 ) 5 CH 3 , and the like.
  • alkyl groups are unsubstituted or substituted with 1 to 3 substituents on each carbon atom, with halo, Ci-C 20 alkyl, CF 3 , NH 2 , N(C C 6 alkyl) 2 , N0 2 , oxo, CN, N 3 , -OH, -0(C C 6 alkyl), C 3 - C10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 alkyl) S(O) 0-2 -, (C 0 -C 6 alkyl)S(O) 0-2 (C 0 - C 6 alkyl)-, (Co-C 6 alkyl)C(0)NH-, H 2 N-C(NH)-, H 2 N-C(0)(NH)-, -0(Ci-C 6 alkyl
  • NHC(0)OCi-C 6 alkyl -NH(Ci-C 6 alkyl)NHS0 2 (Ci-C 6 alkyl), -(C 0 -C 6 alkyl)NHS0 2 (Ci-C 6 alkyl), aryl, aralkyl, heterocycle, heterocyclylalkyl, halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl, cyano-aryl, cyano-aralkyl, cyano-heterocycle and cyano- heterocyclylalkyl.
  • alkenyl means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon double bond.
  • alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1- propenyl, 2-butenyl, 2-methyl-2-butenyl, 2,4-hexadienyl, and the like.
  • alkynyl means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon triple bond.
  • alkynyl include, but are not limited to ethynyl, propargyl, 1-propynyl, 2-butynyl, and the like.
  • carbocycle (and variations thereof such as “carbocyclic” or “carbocyclyl”) as used herein, unless otherwise indicated, refers to (i) a C 3 to C 8 monocyclic, saturated or unsaturated ring or (ii) a C 7 to C 12 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated.
  • the carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
  • Saturated carbocyclics form a subset of carbocycles in which the entire ring system (mono- or polycyclic) is saturated.
  • Saturated monocyclic carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc.
  • the fused bicyclic carbocycles are a further subset of the carbocycles in which a C 7 to C 10 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms (or in the case of spirofused, one carbon atom) are shared by each of the rings in the ring system.
  • a saturated bicyclic carbocycle is one in which both rings are saturated.
  • An unsaturated bicyclic carbocycle is one in which one ring is unsaturated and the other is unsaturated or saturated. Unless otherwise noted, carbocycle is unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, halogen, NH 2 or OH.
  • a subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound.
  • Aromatic carbocycles form another subset of the carbocycles.
  • aryl refers to aromatic mono- and poly-carbocyclic ring systems in which the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenyl.
  • cycloalkyl means a cyclic ring of an alkane having the specified total ring carbon atoms; for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • heterocycle (and variations thereof such as “heterocyclic” or
  • heterocyclyl broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 7- to 12-membered bicyclic ring system, wherein each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized.
  • heteroatoms e.g., from 1 to 6 heteroatoms, or
  • the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
  • the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • saturated heterocyclics form a subset of the heterocycles; i.e., the term “saturated heterocyclic” generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated.
  • saturated heterocyclic ring refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, 1 ,4-dioxanyl, 1 ,4-thioxanyl,
  • Heteroaromatics form another subset of the heterocycles; i.e., the term “heteroaromatic” (alternatively “heteroaryl”) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system.
  • heteroaryl generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system.
  • heteroaryl refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12- membered bicyclic aromatic ring, and which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • substituted heteroaryl rings containing at least one nitrogen atom e.g., pyridine
  • substitutions can be those resulting in N-oxide formation.
  • monocyclic heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • bicyclic heteroaromatic rings include
  • benzotriazolyl indolyl, benzoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, isoindolyl, indazolyl, quinoxalinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrazolo[3,4-b]pyridine, imidazo[2,l-b](l,3)thiazole, (i.e., 6-(l-pyrrolyl)-3 -pyridyl, 4-(l-pyrrolyl)phenyl, 4-(pyrid-3-yl)phenyl, and 4- (pyrid-4-yl)phenyl.
  • heterocycles are unsaturated heterocycles in which one or both rings are unsaturated (provided the entire ring system is not aromatic).
  • unsaturated heterocycles include dihydrofuranyl, dihydrothienyl, dihydropyranyl,
  • dihydroimidazolyl indolinyl, isoindolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyridinyl, 2,3-dihydrobenzofuranyl, 1,4- benzoxazinyl, 1,3-benzoxazolin l 2 3-dih drobenzo-l -dioxinyl (i.e., eft 0 ), and benzo-
  • 1,3-dioxolyl i.e., ).
  • phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms.
  • groups such as chromone and coumarin.
  • cycloalkyl Unless otherwise specifically noted as only unsubstituted or only substituted, cycloalkyl, cycloalkenyl, cycloalkyl, aryl (including phenyl) and heteroaryl groups are unsubstituted or substituted (also referred to as "optionally substituted").
  • substituents for substituted or optionally substituted cycloalkyl, cycloalkenyl, aryl (including phenyl, and as an isolated substituent or as part of a substituent such as in aryloxy and aralkyl), heteroaryl (as an isolated substituent or as part of a substituent such as in heteroaryloxy and heteroaralkyl) are one to three groups independently selected from halogen (or halo), Ci-C 6 alkyl optionally substituted with one to five fluorine, NH 2 , N(Ci-C 6 alkyl) 2 , N0 2 , oxo, CN, N 3 , -OH, -0(Ci-C 6 alkyl) optionally substituted with one to five fluorine, C 3 -Cio cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (Co-C 6 alkyl)S(0)
  • halogen refers to fluorine, chlorine, bromine and iodine
  • fluoro F
  • chloro CI
  • bromo Br
  • iodo I
  • haloalkyl means alkyl having the specified number of carbon atoms in which from one to all of the hydrogen atoms have been replaced by a halogen atom.
  • aralkyl and “heteroaralkyl” refer to an aryl/heteroaryl linked to the rest of the molecule via a Ci to C 4 alkylene.
  • Co as employed in expressions such as "C 0- 6 alkylene” means a direct covalent bond; or when employed in experessions such as "C 0- 6 alkyl” means hydrogen.
  • an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond; for example, in the , wherein s is an integer equal to zero, 1 or 2, the structure is when s is zero; or it means that the indicated atom is absent; for example -S(0)o- means -S-.
  • an “unsaturated” ring is a partially or fully unsaturated ring.
  • an “unsaturated monocyclic C 6 carbocycle” refers to cyclohexene, cyclohexadiene, and benzene.
  • heterocycle described as containing from “ 1 to 4 heteroatoms” means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.
  • any variable occurs more than one time in any constituent or in any formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Ri is a defined variable
  • Rj is a defined variable
  • the value of Ri may differ in each instance in which it occurs, and the value of Rj may differ in each instance in which it occurs.
  • Ri and Rj are independently selected from the group consisting of methyl, ethyl, propyl and butyl
  • (CRiRj) 2 can be
  • the term as used hereinabove means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, n- pentyl and n-hexyl. Preferred is (C 1-4 )alkyl.
  • the term means a branched or unbranched alkyl group having 1-5 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and n-pentyl.
  • the term as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • the term means an alkoxy group having 1-3 carbon atoms, the alkyl moiety being branched or unbranched.
  • the term means an alkoxycarbonyl group having 1-3 carbon atoms in the alkoxy moiety, the alkoxy moiety having the same meaning as previously defined.
  • (di)(Ci-6)alkylaminocarbonyl means an alkylaminocarbonyl group, the amino group of which is monosubstituted or disubstituted independently with an alkyl group which contains 1-6 carbon atoms and which has the same meaning as previously defined.
  • Preferred alkyl group is (C 1-4 )alkyl.
  • (C 3 _7)cycloalkyl means a cycloalkyl group having 3-7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 5-6 Carbon atoms are preferred.
  • heterocycloalkyl means a heterocycloalkyl group having 3-5 carbon atoms, including 1-3 heteroatoms selected from N, O and/or S, which may be attached via a nitrogen if feasible, or a carbon atom.
  • Preferred number of heteroatoms is one or two. Most preferred number is one.
  • Preferred heteroatoms are N or O. Most preferred are piperazinyl, tetrahydropyranyl, morpholinyl and pyrrolidinyl.
  • (C 2 -9)heteroaryl means an aromatic group having 2-9 carbon atoms and 1-3 heteroatoms selected from N, O and S, like imidazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, thiophenyl or furyl, pyrazolyl, isoxazolyl or quinolyl. Preferred number of heteroatoms is one or two. Preferred heteroaryl groups are pyrazolyl, thiophenyl, isoxazolyl, pyridyl and quinolyl.
  • the (C 2 -5)heteroaryl group may be attached via a carbon atom or a nitrogen, if feasible.
  • (C 6- i4)aryl means an aromatic hydrocarbon group having 6-14 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl, anthracyl, More preferred are (C 6- io)aryl groups.
  • the most preferred aromatic hydrocarbon group is phenyl.
  • X a -Xb shall have the same meaning as the term "X a- b", wherein X is any atom and a and b are any integers.
  • C 1 -C4 shall have the same meaning as “C 1-4 ".
  • a x shall have the same meaning, and be interchangeable with, “AX”, wherein “A” is any atom and “x” or “X” are any integer.
  • R 1 shall have the same meaning, and be
  • the attachment point is at the last group.
  • substituted means that one or more hydrogens on the designated atom/atoms is/are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Stable compound or “stable structure” is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. When, in the definition of a substituent, is indicated that "all of the alkyl groups" of said substituent are optionally substituted, this also includes the alkyl moiety of an alkoxy group.
  • salt is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • effective amount refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof, that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a subject suffering from an RORgammaT-mediated disease or disorder.
  • effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.
  • a “subject” is a human or non-human mammal. In one embodiment, a subject is a human. In another embodiment, a subject is a chimpanzee.
  • the compounds of this invention include the prodrugs, hydrates or solvates of the compounds.
  • the compounds of Formula I may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers.
  • the present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers.
  • the above Formula I is shown without a definitive stereochemistry at certain positions.
  • the present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof.
  • Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column.
  • any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g.
  • the compounds of Formula (I) may be atropisomers (e.g. substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column. It is also possible that the compounds of Formula I may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs, such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers.
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts prepared from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources.
  • organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzyl- ethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
  • ethanolamine ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic inorganic and organic acids.
  • Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • the compounds of Formula I can form salts which are also within the scope of this invention.
  • Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
  • pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are
  • salts are well known in the art. They may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like.
  • the acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium carbonate, ammonium (e.g. diethylamine) or lithium hydroxide.
  • solvate refers to a complex of variable stoichiometry formed by a solute (i.e., a compound of Formula I) or a pharmaceutically acceptable salt thereof and a solvent that does not interfere with the biological activity of the solute.
  • solvents include, but are not limited to water, ethanol, and acetic acid.
  • the solvent is water
  • the solvate is known as hydrate; hydrate includes, but is not limited to, hemi-, mono, sesqui-, di- and trihydrates.
  • the compounds of the invention may form hydrates or solvates.
  • Solids of the invention may also mean a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • Solvate encompasses both solution-phase and isolatable solvates.
  • suitable solvates include ethanolates, methanolates, and the like.
  • the present invention includes within its scope the use prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various conditions described with a compound of formula I or with a compound which may not be a compound of formula I, but which converts to a compound of formula I in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.
  • prodrugs means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula I or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I.
  • different isotopic forms of hydrogen (H) include protium (1H) and deuterium ( 2 H).
  • Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
  • Compounds of the present invention are inhibitors of Retinoic Acid Receptor-related Orphan Receptor gamma t (RORgammaT), and as such are useful in the treatment of diseases and conditions in which inhibition of RORgammaT is desirable, such as autoimmune and inflammatory diseases and disorders.
  • RORgammaT Retinoic Acid Receptor-related Orphan Receptor gamma t
  • another embodiment of the present invention provides a method for treating a disease or condition mediated by RORgammaT in a subject comprising
  • the compounds according to the invention can be used in therapy.
  • a further aspect of the invention resides in the use of compounds according to the invention or a pharmaceutically acceptable salt thereof for the treatment of RORgammaT- mediated diseases or RORgammaT mediated conditions.
  • Another aspect of the invention resides in the use of compounds or a pharmaceutically acceptable salt thereof having the general formula I for the treatment of autoimmune diseases, in particular those diseases in which Thl7 cells and non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role.
  • autoimmune diseases in particular those diseases in which Thl7 cells and non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role.
  • These include, but are not limited to, the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.
  • compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of inflammatory diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to respiratory diseases, osteoarthritis and asthma.
  • compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of infectious diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to mucosal leishmaniasis.
  • Compounds or a pharmaceutically acceptable salt thereof having the general formula I can also be used for treatment of other diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to Kawasaki disease and Hashimoto's thyroiditis.
  • the disease or condition is an autoimmune disease or inflammatory disease.
  • the disease or condition includes, but is not limited to, multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
  • the compounds according to the invention can be used in therapies to treat or prevent multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis and mucosal leishmaniasis.
  • the compounds according to the invention can be used to treat or prevent psoriasis.
  • the compounds according to the invention can be used to treat inflammatory bowel disease.
  • This aspect of the present invention further includes the use of a compound of Formula I, la, lb, Ic, Id or Ie, or a pharmaceutically acceptable salt or solvate thereof, in the
  • the compounds of this invention can be administered for the treatment or prevention of afflictions, diseases and illnesses according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal.
  • administration can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravaginal, rectal, intracisternal and parenteral.
  • parenteral refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrasternal and intraperitoneal.
  • a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
  • the compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
  • a daily dosage of active ingredient compound will be from about 1.0-2000 milligrams per day. Ordinarily, from 10 to 500 milligrams per day in one or more applications is effective to obtain desired results.
  • These dosages are the effective amounts for the treatment and prevention of afflictions, diseases and illnesses described above, e.g., autoimmune and inflammatory diseases and disorders.
  • compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, nasal, local, or rectal administration, and the like, all in unit dosage forms for administration.
  • the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • sterile liquid carrier e.g. water
  • the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
  • the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
  • solid dosage units For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used.
  • Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
  • aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing
  • dispersing agents and/or wetting agents such as propylene glycol or butylene glycol.
  • compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients.
  • excipient and “carrier” may be used interchangeably.
  • composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions.
  • solid dosage forms such as capsules, tablets, troches, dragees, granules and powders
  • liquid dosage forms such as elixirs, syrups, emulsions, dispersions, and suspensions.
  • the active ingredient can also be
  • sterile liquid dosage forms such as dispersions, suspensions or solutions.
  • Other dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
  • Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
  • the compounds of the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
  • the compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
  • the preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons.
  • MDI metered dose inhalation
  • an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of Formula I in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
  • Useful pharmaceutical dosage-forms for administration of the compounds of this invention include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
  • a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient.
  • the capsules are washed and dried.
  • a large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
  • Appropriate coatings may be applied to increase palatability or delay absorption.
  • a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
  • An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S. P., and 0.025 milliliters of vanillin.
  • the same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction with another therapeutic agent.
  • the dosage form and administration route should be selected depending on the compatibility of the combined drugs.
  • coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof having the general formula I in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
  • the auxiliaries must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • compositions thereof may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered. In general parenteral administration requires lower dosages than other methods of administration which are more dependent upon absorption. However, a dosage for humans preferably contains 0.0001-100 mg per kg body weight. The desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day. The dosage as well as the regimen of administration may differ between a female and a male recipient.
  • Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other pharmaceutically active agent.
  • the compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order.
  • a compound of formula (I) may be combined with one or more other active agents such as: (1) TNF-a inhibitors; (2) non- selective COX-I/COX-2 inhibitors; (3) COX-2 inhibitors; (4) other agents for treatment of inflammatory and autoimmune diseases including glucocorticoids, methotrexate, leflunomide, sulfasalazine, azathioprine, cyclosporin, tacrolimus, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, ciclesonide, hydroxychloroquine
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
  • These combinations are of particular interest in respiratory diseases and are conveniently adapted for inhaled or intranasal delivery.
  • the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
  • the individual compounds will be administered simultaneously in a combined pharmaceutical composition.
  • Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
  • compositions of the present invention include those that also comprise at least one additional therapeutically active agent, in addition to the compound of Formula I, la, lb, Ic, Id or Ie.
  • the invention further includes a compound of Formula I in combination with one or more other drug(s).
  • ferrocene ]dichloropalladium (II); BnBr: Benzyl bromide; DAST: (Diethylamino)sulfur trifluoride; Ac 2 0: Acetic an hydride; LiHMDS: Lithium bis(trimethylsilyl)amide; PhNTf 2 : N- Phenyl-bis(trifluoro methanesulfonimide); S-Phos: 2-Dicyclohexylphosphino-2',6'- dimethoxybiphenyl; X-Phos: 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; CPME: Cyclopentyl methyl ether.
  • Example i-1 Preparation of methyl 2-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzoate (i-1) Scheme i-1.
  • Methyl 4- (benzyloxy)-2-(trifluoromethylsulfonyloxy)benzoate (i-lc) (6.8 g, 17.4 mmol), 4,4,5,5- tetramethyl-2-(prop-l-en-2-yl)-l ,3,2-dioxaborolane (2.9 g, 17.4 mmol), Pd(OAc) 2 (195 mg, 0.87 mmol), S-Phos (71 mg, 0.174 mmol) and K 3 PO 4 (1 1 g, 52 mmol) were mixed in THF (70 ml). The mixture was stirred at 75 °C for 24 h. The mixture was diluted with H 2 0, and extracted with EtOAc. The combined organics were dried and concentrated.
  • Example i-4 Preparation of methyl 2,5-difluoro-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzoate (i-4) i) Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2- yl)benzoate (i-4). To a flask was added compound (i-4a) (412 mg, 2.0 mmol), compound (i- 2c) (1.52 g, 6 mmol), X-Phos (95 mg, 0.2 mmol), Pd(OAc) 2 (44 mg, 0.2 mmol) and CPME (20 mL).
  • Example i-7 methyl 5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2-yl)benzoate (i-7)
  • heterocyclic derivatives of Formula I wherein A 4 to A 7 , R 1 , R 2 , R 3 , X and Y are as previously defined, can be prepared from compounds II.
  • Palladium catalyzed Suzuki- Miyaura arylation of compounds II using appropriately substituted phenylboronic acids Ill-a (corresponding boronic esters Ill-b may also be used) directly affords the desired compounds I.
  • aqueous NaOH, K 2 C0 3 or the like) and an aryl boronic acid of general Formula III- a or aryl boronic ester of general formula Ill-b in a suitable solvent such as dioxane or toluene/EtOH, is heated under an atmosphere of nitrogen under microwave irradiation or using conventional heating.
  • compound I may be obtained from compounds of Formula IV, in which FG is a functional group (e.g. ester, cyano, protected tetrazole) that can be easily converted to groups defined for R 2 .
  • suitable functional groups in compounds IV are a tert-butyl ester or methyl ester or a tetrazole, containing an acid labile group such as a? ra-methoxy benzyl protecting group, which can be treated with acid or base to afford compounds of Formula I-a or I-b in which R 2 is carboxyl or 5-tetrazolyl, respectively.
  • Compounds II are prepared by straightforward acylation or sulfonylation of compounds V.
  • a strong base such as potassium tert- butoxide or NaH
  • a suitable solvent such as DMF or THF
  • treatment of V with sulfonyl chlorides and a tertiary amine base e.g. DiPEA or triethylamine
  • a solvent such as dichloromethane
  • acid chlorides are not available, they can be easily prepared from the corresponding carboxylic acids using known methods (e.g. treatment with SOCl 2 or similar reagents).
  • Compounds V are commercially available or prepared by methods know in the art, such as halogenation of compounds VI.
  • Compounds VI are also commercially available or easily prepared by standard organic synthesis techniques.
  • Compounds IV can be prepared in the same way as compounds I, by Suzuki-Miyaura reaction between compounds of general Formula II and an appropriately substituted arylboronic acid or ester.
  • Hal Br, CI, I ⁇ , ⁇ I V-U. A - U
  • Electro Spray spectra were recorded on the Applied Biosystems API- 165 single quad MS in alternating positive and negative ion mode using Flow Injection. The mass range was 120-2000 Da and scanned with a step rate of 0.2 Da. and the capillary voltage was set to 5000 V. N2-gas was used for nebulasation.
  • UPLC Water acquity UPLC system; Column : BEH C18 1.7 ⁇ , 2.1 x 100 mm, Detector: PDA (200-320 nm), Mass detector: SQD
  • step ii) Following a procedure analogous to that described in Example 1, step ii, using 1,1,1,3,3,3- hexafluoro-2-(4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol as the boronic ester, the title compound 1,1,1 ,3 ,3 ,3-hexafluoro-2-(4-(l -(2-
  • reaction mixture was stirred at 150 °C in a microwave reactor for lh
  • step iii Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-( 1 -(2-(trifluoromethvnphenylsulfonyl -iH-indazol-3-yl)benzoic acid, was prepapred (28 mg)
  • step iii Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(l-(2-cyanophenylsulfonyl)-iH-indazol-3-yl)benzoic acid, was prepapred (13 mg)
  • reaction mixture 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with water and washed with ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate.
  • trimethylsilyl azide (4.02 g, 35 mmol) and dibutyl-stannanone (434 mg, 1.75 mmol) were added into each microwave vessel and the mixtures were irradiated again at 150 °C for 10 min. After cooling to room temperature, the mixtures were combined and purified by column chromatography on florisil (200 g). It was first eluted with 20% dichloromethane in hexane to remove the impurities, then with 10% methanol in dichloromethane to elute the product.
  • step ii) (7.92 g, 20.2 mmol) were dissolved in 100 ml of a 1 to 1 mixture of 1,4-dioxane and water under a nitrogen atmosphere.
  • step i) To a solution of a mixture of regio-isomers of 3-(4-(l-(4-Methoxybenzyl)-7H-tetrazol-5- yPphenyl H-indazole (Example 20, step i) (50 mg, 0.13 mmol) was dissolved in anhydrous THF (1 ml). After addition of t-BuOK (16 mg, 0.14 mmol,) the reaction mixture was stirred at room temperature for 15 min. Subsequently, 2,6-dichlorobenzoyl chloride (21 ⁇ , 0.14 mmol) was added and the reaction mixture was stirred for another 2h at room temperature. The solvent was evaporated under reduced pressure, the residue was dissolved in
  • step iii Following a procedure analogous to that described in Example 20, step iii, the product obtained in the previous step was converted to the title compound (3-(4-(7H-tetrazol-5- vDphenyl H-indazol- 1 -yl)(2,6-dichlorophenyl)methanone (16 mg).
  • A-5 A-6 24A i) Preparation of 4-fluoro-3-iodo-/H-indazole (A-2).
  • DMF 80 mL
  • h 18.6 g, 73.5 mmol
  • KOH 7.73 g, 134 mmol
  • the reaction mixture was poured into aq. 10% NaHS0 3 (200 mL) and extracted with EtOAc (200 mL*3).
  • the combined organic layers were washed with H 2 0 and brine, dried over Na 2 S0 4 , and concentrated.
  • the compounds of the invention inhibit RORgammaT activity. Activation of
  • RORgammaT activity can be measured using e.g. biochemical TR-FRET assay.
  • TR-FRET interaction of cofactor-derived peptides with human RORgammaT-Ligand Binding Domain (LBD) can be measured.
  • LBD RORgammaT-Ligand Binding Domain
  • the TR-FRET technique is a sensitive biochemical proximity assay that will give information concerning the interaction of a ligand with the LBD, in the presence of cofactor derived peptides (Zhou et al., Methods 25:54-61, 2001).
  • a peptide from Steroid Receptor Co-factor 1 box 2 (SRC 1 2) is aminoterminal biotinylated (biotinyl-CPSSHSSLTERHKILHRLLQEGSPS, NEOMPS, France) and the applied RORgamma-LBD contains a 6-His and GST tag.
  • 6His(GST)RORgamma-LBD was expressed and purified from baculovirus infected Sf-21 insect cells (Bac-to-BAC, Invitrogen) and purified using glutathione sepharose
  • streptavidin-allophycocyanin Streptavidin-allophycocyanin (Strep-APC, Perkin Elmer, CI 30- 100) and anti-His-Europium Cryptate (Perkin Elmer, AD0111), respectively. Since energy transfer between the streptavidin and His-coupled labels APC and europium cryptate can only take place when these labels are in close proximity, measurement of energy transfer in a mixture of biotinylated peptide, His-GR-LBD, streptavidin- APC and anti-His-Europium Cryptate will be indicative for RORy-LBD/peptide binding.
  • Final assay conditions in 50 ⁇ are: TR-FRET buffer [50 mM KC1, 50 mM TRIS, 1 mM Na-EDTA, 0.1 mM DTT, (pH 7.0)];
  • Dose-response data are curve-fitted (IBDS Software, ActivityBase) and pEC50 values calculated.
  • pEC50 values for Examples 1-23 using Protocol A are provided in Table 6 below. All compounds of the invention have a pEC50 of 4 or higher. Preferred are compounds with a pEC50 of more than 5.
  • HIS-tagged RORy-LBD was recombinantly expressed in SF9 cells using a baculovirus expression system. The protein was not purified. Cells were lysed and the lysate was used as a source for RORy-LBD for the assay. A 1 :80 dilution of RORy-LBD lysate in assay buffer (25 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Tween, 0.1% BSA) was prepared and 5 was added to each well (RORy-LBD final concentration ⁇ 10 nM). Control wells received lysate from SF9 cells not expressing RORy-LBD.
  • assay buffer 25 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Tween, 0.1% BSA
  • a 4x stock of biotinylated-LXXLL peptide from SRC 1-2 was prepared in assay buffer and & 5 ⁇ , aliquot added to each well (450 nM final concentration).
  • a 4x solution of europium tagged anti-HIS antibody (2 nM final concentration) and APC conjugated streptavidin (60 nM final concentration) were prepared and & 5 ⁇ , aliquot added to each well.
  • IC50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm using GraphPad Prism software.
  • HIS-tagged RORy-LBD protein was expressed in SF9 cells using a baculovirus expression system.
  • the RORy-LBD protein was purified by glutathione sepharose chromatography. Separately, SF9 cells not expressing any recombinant protein were lysed and the lysate was added to the purified RORy-LBD at 0.25 ⁇ lysate (from 10,000 SF9 cells)/nM purified protein. The mixture was then diluted in assay buffer (50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT) to obtain RORy-LBD final concentration of 3 nM in 384-well assay plate.
  • assay buffer 50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT
  • a stock of biotinylated-LXXLL peptide from coactivator SRC1 (Biotin- CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and added to each well (100 nM final concentration).
  • Table 7 below tabulates the biological data disclosed for Examples 24A-29 as a range of Fret IC 50 values, which was reported as ranges according to the annotation delineated below:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.

Description

RORgammaT INHIBITORS
BACKGROUND OF THE INVENTION
Upon activation by antigen-presenting cells naive T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Thl and Th2 subtypes. A third and distinct effector subset has been identified, which plays a key role in providing immunity to bacteria and fungi at mucosal surfaces (Kastelein et al., Annu. Rev. Immunol. 25: 221-242, 2007). This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17/F, IL-21 and IL-22, and is named Thl7 (Miossec et al, New Eng. J. Med. 2361 : 888-898, 2009).
Different T helper subsets are characterized by the expression of lineage specific master transcription factors. Thl and Th2 effector cells express Tbet and GATA3, respectively. A Thymocyte/T cell specific variant of Retinoic Acid Receptor-related Orphan Receptor (ROR), RORgammaT, is highly expressed in Thl7 cells (He et al., Immunity 9: 797-806, 1998).
RORgammaT belongs to the nuclear hormone receptor superfamily (Hirose et al., Biochem. Biophys. Res. Comm. 205: 1976-1983, 1994). RORgammaT is a truncated form of
RORgamma, lacking the first N-terminal 21 amino acids and is, in contrast to RORgamma which is expressed in multiple tissues (heart, brain, kidney, lung, liver and muscle), exclusively expressed in cells of the lymphoid lineage and embryonic lymphoid tissue inducers (Sun et al., Science 288: 2369-2372, 2000; Eberl et al., Nat Immunol. 5: 64-73, 2004).
Studies using heterozygous knock-in mice replacing the RORgammaT open reading frame with GFP, revealed a constitutive expression of GFP in approximately 10% of the CD4+ T cells in the small intestinal lamina propria (LP), co-expressing the Thl 7 cytokines IL-17/F and IL-22 (Ivanov et al, Cell 126: 1121-1133, 2006). In mice deficient for
RORgammaT, the number of Thl 7 cells was markedly decreased in the LP and in vitro stimulation of CD4+ T cells, under Thl 7 polarizing conditions resulted in a drastic decrease of IL-17 expression. These results were further substantiated via forced expression of
RORgammaT in na'ive CD4+ T cells, which resulted in an induction of IL-17/F and IL-22 (Ivanov et al., Cell 126: 1121-1133, 2006). Taken together demonstrating the importance of RORgammaT in differentiation and stabilization of the Thl 7 lineage. In addition, a ROR family member, RORalpha has been demonstrated to be involved in Thl7 differentiation and stabilization (Yang et al., Immunity 28: 29-39, 2008).
Recently, RORgammaT was shown to play a crucial role in non-Thl7 lymphoid cells. In these studies, RORgammaT was critically important in innate lymphoid cells expressing Thyl, SCA-1 and IL-23R proteins. Genetic disruption of RORgamma in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development (Buonocore et al., Nature 464: 1371-1375, 2010). In addition, RORgammaT was shown to play a crucial role in other non-Thl7 cells, such as mast cells (Hueber et al., J Immunol. 184: 3336-3340, 2010). Finally, RORgammaT expression and secretion of Thl7-type of cytokines was reported for Lymphoid Tissue Inducer cells, NK T-cells, NK cells (Eberl et al., Nat. Immunol. 5: 64-73, 2004) and gamma-delta T-cells (Sutton et al, Nat. Immunol. 31 : 331-341, 2009; Louten et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009), suggesting an important function for RORgammaT in these subtypes of cells.
Based on the role of IL-17 producing cells (either Thl7 or non-Thl7 cells)
RORgammaT has been identified as a key mediator in the pathogenesis of several diseases (Louten et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009; Annuziato et al., Nat. Rev. Rheumatol. 5: 325-331, 2009). This was confirmed using several disease models
representative of autoimmune diseases. Genetic ablation of the RORgamma gene in mice prevented the development of experimental autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and colitis (Ivanov et al., Cell 126: 1121-33, 2006; Buonocore et al, Nature 464: 1371-1375, 2010).
Being a critical mediator in Thl7-cells and other non-Thl7 cells, inhibition of
RORgammaT is expected to have a beneficial effect on autoimmune diseases, such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and asthma (Annunziato et al., Nat. Rev. Immunol. 5: 325-331, 2009; Louten et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009). Inhibition of RORgammaT may also be beneficial in other diseases, which are characterized by increased levels of Thl7 cells and/or elevated levels of Thl7 hallmark cytokines such as IL-17, IL-22 and IL-23. Examples of such diseases are Kawasaki Disease (Jia et al., Clin. Exp. Immunol. 162: 131-137, 2010) and Hashimoto's thyroiditis (Figueroa-Vega et al., J Clin. Endocrinol. Metab. 95: 953-62, 2010). Another example includes infectious diseases, such as, but not limited to, mucosal leishmaniasis (Boaventura et al., Eur. J. Immunol. 40: 2830-2836, 2010). In each of the above examples the inhibition may be enhanced by simultaneous inhibition of RORalpha.
Compounds modulating RORgammaT have been reported. Examples of agonists include T0901317 and SR1078 (Wang et al, ACS Chem. Biol. 5: 1029-1034, 2010). In addition, antagonist have been reported such as 7-oxygenated sterols (Wang et al., J Biol. Chem. 285: 5013-5025, 2009) and compounds described in EP2181710 Al .
Numerous immune and inflammatory disorders continue to afflict millions of patients worldwide. Although significant advances have been made in treating these disorders, current therapies do not provide satisfactory results for all patients due to, for example, detrimental side effects or insufficient efficacy. One exemplary immue disorder in need of better therapy is psoriasis. Various therapeutics have been developed in an attempt to treat psoriasis.
However, the traditional therapies for psoriasis often have toxic adverse effects. An exemplary inflammatory disorder in need of better treatment is rheumatoid arthritis.
Numerous therapeutics have been developed in an attempt to treat this disorder. However, some patients develop resistance to current therapies.
Accordingly, a need exists for improved treatments for immune disorders and inflammatory disorders. The present invention addresses this need and provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides compounds which inhibit RORgammaT, their use for the treatment of RORgammaT-mediated diseases or conditions, in particular autoimmune diseases and inflammatory diseases, as well as pharmaceutical compositions comprising such compounds and pharmaceutical carriers.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a compound according to Formula I
Figure imgf000005_0001
I or a pharmaceutically acceptable salt or solvate thereof wherein,
X is C(O), SO or S02,
Y is CH or N;
n = 0, 1, 2, 3 or 4;
4 7 4 5 6 7
A -A are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A4-A7 can be simultaneously N;
R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci_
3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci. 3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci_
3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci_ 3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens; or (iii) (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci_
3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci_ 3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy are optionally substituted with one or more halogens;
R2 is C(0)OH, 5-tetrazoylyl, HOC(CF3)2, C(0)OH(Ci.io)alkyl, (Ci.
io)alkylsulfoxyaminocarbonyl; or carbamoyl;
R3 is hydrogen, halogen, cyano, nitro, hydroxy, (Cl-3)alkylC(0)0-, (Ci-4)alkyl, or (Ci_ 4)alkoxy, wherein (Ci-4)alkyl and (Ci_4)alkoxy are optionally substituted with one or more halogens;
R4-R7 independently are H, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, (Ci-4)alkyl, (C0- io)alkyl)aminocarbonyl, (di)(Ci-6)alkylaminocarbonyl or amino(Ci-4)alkyl, wherein (Ci_ 3)alkoxy, (Ci-4)alkyl, (Co-io)alkyl)aminocarbonyl, (di)(Ci.6)alkylaminocarbonyl and amino(Ci. 4)alkyl are optionally substituted with one or more halogen, hydroxyl or (Ci-3)alkoxy; or a group having the
Figure imgf000006_0001
, optionally substituted with one or more of the following: (Ci-io)alkyl, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, and wherein m is 1, 2, 3, or 4.
This invention also provides a compound according to Formula la
Figure imgf000006_0002
la or a pharmaceutically acceptable salt or solvate thereof
wherein X represents C(O), SO or S02,
Y is CH or N;
4 7 4 5 6 7
A -A' are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A4-A7 can be simultaneously N;
R1 is (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H2NC(0)-, or (Ci-3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogens or; R1 is (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, or (Ci-3)alkoxycarbonyl, (di)(Ci.
6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogens or;
R1 is (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, or (Ci-3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci_ 4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogens;
R2 is C(0)OH, 5-tetrazoylyl, or HOC(CF3)2;
R3 is independently selected from hydrogen, halogen, cyano, nitro or (Ci-4)alkyl, optionally substituted with one or more halogens; and
R4-R7 independently are H, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, (Ci-4)alkyl, optionally substituted with one or more halogens.
In the first embodiment of the compounds of Formula I and la are compounds wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; (iii) CR4, N, CR6, CR7; (iv) CR4, CR5, N, CR7; (v) CR4, CR5, CR6, N; (vi) N, N, CR6,CR7; (vii) CR4, N, N, CR7; (viii) CR4, CR5, N, N; (ix) N, CR5, N, CR7; (x) CR4, N, CR6, N; and (xi) N, CR5, CR6, N.
In a subset of the first embodiment are compounds wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; and (iii) CR4, N, CR6, CR7.
In a second subset of the first embodiment are compounds wherein A4, A5, A6, A7 is (i) CR4, CR5, CR6, CR7, or (ii) N, CR5, CR6, CR7; and Y is N.
In a third subset of the first embodiment are compounds wherein
X is C(O) or S02;
R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from (Ci-4)alkyl or halogen; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (Ci-4)alkyl; or (iii) (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci-3)alkoxycarbonyl, (Ci-4)alkyl, (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (Ci_ 4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens. In a fourth subset of the first embodiment are compounds wherein
R1 is (C2-9)heteroaryl or (C6-i4)aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci-3)alkoxycarbonyl, (Ci-4)alkyl or (C\. 3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally
substituted with one or more halogen.
In a fifth subset of th first embodiment are compounds according to Formula I wherein Rl is (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, or (Ci-3)alkoxycarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogen.
In a sixth subset of the first embodiment are compounds wherein R1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci_
3)alkoxycarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens.
In a seventh subset of the first embodiment are compounds according to Formula I and la wherein (C6-i4)aryl in R1 is phenyl.
In an eighth subset of the of the first embodiment are compounds wherein R1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci-3)alkoxycarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens.
In a ninth subset of the first embodiment, are compounds wherein R2 is C(0)OH.
A tenth subset of the invention relates to compounds according to Formula I and la wherein Y is N.
In a second embodiment of the compound of Formula I is a compound having Formula lb
Figure imgf000009_0001
lb and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R^R3, X, Y and n are defined as set forth hereinabove for Formula I.
In a third embodiment of the compound of Formula I is a compound having Formula Ic
Figure imgf000009_0002
Ic or a pharmaceutically acceptable salt or solvate thereof wherein,
X is C(O) or S02
R is selected from halogen, amino, cyano, nitro, hydroxy, H2NC(
(di)(Ci-6)alkylaminocarbonyl, wherein
(di)(Ci-6)alkylaminocarbonyl,
Figure imgf000009_0003
are optionally substituted with one or more halogens;
x is 0, 1, 2, 3, 4 or 5; and A4-A7, RJ-R3, Y and n are defined as set forth hereinabove for Formula I.
In a fourth embodiment of the compound of Formula I is a compound having Formula
Id
Figure imgf000010_0001
Id and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R2, R3, X, Y and n are defined as set forth hereinabove for Formula I.
In a fifth embodiment of the compound of Formula I is a compound having Formula Ie
Figure imgf000010_0002
le and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R3, X and n are defined as set forth hereinabove for Formula I.
In a further embodiment of the compounds of Formula I, la, lb, Ic, Id, and le, are compounds wherein
R4 is selected from H, halogen, amino, and
Figure imgf000011_0001
optionally substituted with one or more halogen;
R5 is H;
R6 is selected from H, dimethylaminocarbonyl, -CH2NH2, cyano,
Figure imgf000011_0002
onally substituted with one or more halogen, hydroxyl,
-CH2OH, -CH2OCH3 or methoxy; and
R7 is selected from H and halogen.
A still further embodiment of the compounds of Formula I, la, lb, Ic, Id, and le, are compounds wherein one of R4, R5 and R7 is other than hydrogen.
The invention also relates to those compounds wherein all specific definitions for A1 through A4, R1 through R8, X, Y, n and x and all substituent groups in the various aspects of the inventions defined here above occur in any combination within the definition of the compound of Formula I.
Non-limiting examples of the compunds of the present invention include:
4-(l-(2,6-dichlorobenzoyl)-lH-indazol-3-yl)benzoic acid;
4-( 1 -(2,6-dichlorobenzoyl)-5 -fluoro- 1 H-indazol-3 -yl)benzoic acid;
4-( 1 -(2,6-dichlorobenzoyl)-7-fluoro- 1 H-indazol-3 -yl)benzoic acid;
4-( 1 -(2,6-dichlorobenzoyl)-4-fluoro- 1 H-indazol-3 -yl)benzoic acid;
4-( 1 -(2,6-dichlorobenzoyl)-6-fluoro- 1 H-indazol-3 -yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
4-(l-(2-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid; -( 1 -(2,6-dichlorobenzoyl)- 1 H-pyrrolo [3 ,2-b]pyridin-3 -yl)benzoic acid;
-(l-(2,6-dichlorobenzoyl)-lH-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
,1,1 ,3 ,3 ,3 -hexafluoro-2-(4-( 1 -(2-(trifluoromethyl)phenylsulfonyl)- 1 H-indazol-3 - yl)phenyl)propan-2-ol;
-(l-(2-(trifluoromethyl)benzoyl)-l H-indazol-3 -yl)benzoic acid;
-( 1 -(3 ,5 -dichloroisonicotinoyl)- 1 H-indazol-3 -yl)benzoic acid;
-(l-(2-bromobenzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2-(methoxycarbonyl)benzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(cyclohexanecarbonyl)-l H-indazol-3 -yl)benzoic acid;
-( 1 -(2-bromo-6-chlorobenzoyl)- 1 H-indazol-3 -yl)benzoic acid;
-(l-(2-fluoro-6-(trifluoromethyl)benzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2-fluoro-6-methoxybenzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2,4,6-trichlorobenzoyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2,6-dimethylbenzoyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2-ethoxybenzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2,3-dichlorobenzoyl)-lH-indazol-3-yl)benzoic acid;
-( 1 -(2-chlorobenzoyl)- 1 H-indazol-3 -yl)benzoic acid;
-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2-methyl-6-nitrobenzoyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2-(trifluoromethyl)phenylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(quinolin-8-ylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2-bromophenylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2,5-dichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(3-chloro-2-methylphenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2,3-dichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2,3,4-trichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(2-cyanophenylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2-(trifluoromethoxy)phenylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(naphthalen-l-ylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
-(l-(2,6-dichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
-(l-(benzo[c][l,2,5]oxadiazol-4-ylsulfonyl)-lH-indazol-3-yl)benzoic acid;-(l-(2-cyano-5-methylphenylsulfonyl)-l H-indazol-3 -yl)benzoic acid; 4-(l-(3,5-dimethylphenylsulfonyl)-lH-indazol-3-yl)-3-fluorobenzoic acid;
4-(l-(3,5-dimethylphenylsulfonyl)-lH-indazol-3-yl)-2-(trifluoromethyl)benzoic acid;
4-(l-(2-chlorophenylsulfonyl)-lH-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
3 -(4-( 1 H-tetrazol-5 -yl)phenyl)- 1 -(3-chlorophenylsulfonyl)- 1 H-indazole;
methyl 3 -(3 -(4-(l H-tetrazol-5 -yl)phenyl)-lH-indazol-l-ylsulfonyl)thiophene-2-carboxylate;
3 -(4-( 1 H-tetrazol-5 -yl)phenyl)- 1 -(2-bromo-4-fluorophenylsulfonyl)- 1 H-indazole;
3 - (4-(l H-tetrazol-5 -yl)phenyl)-l -(3 -bromo-5 -chlorothiophen-2-ylsulfonyl)-l H-indazole;
4- (3-(4-(l H-tetrazol-5 -yl)phenyl)-lH-indazol-l-ylsulfonyl)-3, 5 -dimethylisoxazole;
(3-(4-(lH-tetrazol-5-yl)phenyl)-lH-indazol-l-yl)(2,6-dichlorophenyl)methanone;
(3-(4-(lH-tetrazol-5-yl)phenyl)-lH-indazol-l-yl)(2,3-dichlorophenyl)methanone;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-lH-indazol-3-yl)-3- fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH- indazol-3-yl)-3-fluorobenzoic acid; Sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-lH-indazol-3-yl)-3- fluorobenzoate;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3- yl)benzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- indazol-3-yl)benzoate;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- pyrazolo[4,3-b]pyridin-3-yl)-3- fluorobenzoate;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- pyrazolo[4,3-b]pyridin-3-yl)-3- fluorobenzoate;
(2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-(4-(l , 1,1,3, 3,3-hexafluoro-2-hydroxypropan- 2-yl)phenyl)- 1 H-indazol- 1 -yl)methanone;
3- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzoic acid;
2-(3-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)phenyl)acetic acid; 2-(4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)phenyl)acetic acid; 2-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzoic acid; Sodium 3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3- yl)benzoate;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzamide; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-fluoro-5- methylbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3-methylbenzoicacid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-methoxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-fluorobenzoic acid; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2- fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-methylbenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3-methoxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,6-difluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-isopropylbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3,5-dimethoxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-cyano benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,3-difluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,5-difluorobenzoic acid;
2- chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5- fluorobenzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5-fluoro-2- methoxybenzoic acid;
5- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-hydroxybenzoic acid;
3- fluoro-4-(4-fluoro-l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
4- (4-fluoro- 1 -(2-fluoro-6-methoxybenzoyl)- 1 H-indazol-3-yl)benzoic acid;
3-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl) benzoic acid; 2-(4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl) phenyl)acetic acid; (2-chloro-6-(trifluoromethyl)phenyl)(3-(4-(l ,1 , 1 ,3,3,3-hexafluoro-2-hydroxypropan-2- yl)phenyl)-lH-pyrazolo[4,3-b]pyridin-l-yl)methanone;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-3-methylbenzoic acid;
3- chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3- yl)benzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2-fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- methoxybenzoic acid;
2- chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-5- fluorobenzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2,5- difluorobenzoic acid;
5- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- hydroxybenzoic acid;
4-(l-(2-fluoro-6-methoxybenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
3- fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-(trifluoromethyl)-lH-indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-2-isopropylbenzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-2-fluoro benzoate; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-3-fluoro benzoate; 3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)benzoic acid;
3- fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
sodium 3-fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoate;
4- (7-fluoro- 1 -(2-fluoro-6-methoxybenzoyl)- 1 H-indazol-3-yl)benzoic acid;
3- fluoro-4-(7-fluoro-l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
4- (6-bromo-l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl) benzoic acid; 4-(6-bromo-l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-methoxy-lH-indazol-3-yl) benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl)benzoic acid; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl) benzoate; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl)-3-fluorobenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-lH-indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-lH-indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(methoxymethyl)-lH-indazol-3-yl)benzoic acid; l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-lH-indazole-6- carboxylic acid;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2- hydroxyethylcarbamoyl)-lH- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)-lH-indazol-3- yl)benzoic acid;
sodium 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6- (2-hydroxyethylcarbamoyl)- 1 H- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3- yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol-3- yl)benzoic acid;
sodium 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)- 1 H- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-3- fluorobenzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)- 3-fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol-3-yl)-2- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol-3-yl)-3- fluorobenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-2- fluorobenzoic acid;
3 -chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-l H-indazol-3 - yl)benzoic acid;
3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH- indazol-3-yl)benzoic acid;
l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-l H-indazol-3 - yl)benzoic acid;
l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-l H-indazol-3 -yl)- 3-fluorobenzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-methoxypropylcarbamoyl)-l H-indazol-3 -yl)- 3-fluorobenzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxypropylcarbamoyl)-l H-indazol-3 - yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(4-hydroxybutylcarbamoyl)-l H-indazol-3 - yl)benzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-lH- indazol-3-yl)benzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-lH- indazol-3-yl)-3-fluorobenzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-methoxyethyl)(methyl)carbamoyl)-lH- indazol-3 -yl)-3 -fluorobenzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-fluoroazetidine-l -carbonyl)- 1 H-indazol-3 - yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3, 3 -difluoroazetidine-1 -carbonyl)- lH-indazol- 3-yl)benzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-6-(pyrrolidine-l -carbonyl)- 1 H-indazol-3 - yl)benzoic acid;
(azetidine- 1 -carbonyl)- 1 -(2-chloro-6-(trifluoromethyl)benzoyl)- 1 H-indazol-3 -yl)benzoic acid;
(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH- indazol-3 -yl)-2-hydroxybenzoic acid; 2-acetoxy-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-lH-indazol-3-yl)benzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)- 4-fluoro-lH-indazol-3-yl)-2- hydroxybenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-fluoro-6- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3-hydroxybenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5-fluoro-2- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3,6-difluoro-2- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- hydroxybenzoic acid;
2-acetoxy-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3- yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-2- hydroxybenzoic acid;
4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl) benzoyl)- lH-indazol-3-yl)benzoic acid; 4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-2-(difluoro methyl)benzoic acid; and
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-lH- indazol-3-yl)benzoic acid.
The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding, and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "hydroxyalkyl," "fluoroalkyl," "alkoxy", etc.
As used herein, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
The term "alkyl," as used herein, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond having the specified number of carbon atoms. In different embodiments, an alkyl group contains, for example, from 1 to 6 carbon atoms (Ci- C6 alkyl) or from 1 to 3 carbon atoms (C1-C3 alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched.
Unless specified otherwise, "alkyl" includes both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms; for example, "C1-6 alkyl" (or "Ci-C6 alkyl") includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
"Alkylene" refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments; for example, the term "A-C4alkylene-B" represents, for example, A-CH2- CH2-CH2-CH2-B, A-CH2-CH2-CH(CH3)-CH2-B, A-CH2-CH(CH2CH3)-B, A-CH2- C(CH3)(CH3)-B, and the like. "Alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; for example "Ci-Ce alkoxy" includes -OCH3, -OCH2CH3, -OCH(CH3)2, -0(CH2)5CH3, and the like.
Unless otherwise specifically noted as only "unsubstituted" or only "substituted", alkyl groups are unsubstituted or substituted with 1 to 3 substituents on each carbon atom, with halo, Ci-C20 alkyl, CF3, NH2, N(C C6 alkyl)2, N02, oxo, CN, N3, -OH, -0(C C6 alkyl), C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C0-C6 alkyl) S(O)0-2-, (C0-C6 alkyl)S(O)0-2(C0- C6 alkyl)-, (Co-C6 alkyl)C(0)NH-, H2N-C(NH)-, H2N-C(0)(NH)-, -0(Ci-C6 alkyl)CF3, (C0- C6 alkyl)C(O)-, (C0-C6 alkyl)OC(O)-, (C0-C6 alkyl)0(d-C6 alkyl)-, (C0-C6 alkyl)C(O)i-2(C0- C6 alkyl)-, (Co-C6 alkyl)OC(0)NH-, -NH(Ci-C6 alkyl)NHC(0)NH(Ci-C6 alkyl),
NHC(0)OCi-C6 alkyl, -NH(Ci-C6 alkyl)NHS02(Ci-C6 alkyl), -(C0-C6 alkyl)NHS02(Ci-C6 alkyl), aryl, aralkyl, heterocycle, heterocyclylalkyl, halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl, cyano-aryl, cyano-aralkyl, cyano-heterocycle and cyano- heterocyclylalkyl.
The term "alkenyl" means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon double bond. Examples of alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1- propenyl, 2-butenyl, 2-methyl-2-butenyl, 2,4-hexadienyl, and the like.
The term "alkynyl" means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon triple bond. Examples of alkynyl include, but are not limited to ethynyl, propargyl, 1-propynyl, 2-butynyl, and the like.
The term "carbocycle" (and variations thereof such as "carbocyclic" or "carbocyclyl") as used herein, unless otherwise indicated, refers to (i) a C3 to C8 monocyclic, saturated or unsaturated ring or (ii) a C7 to C12 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
Saturated carbocyclics form a subset of carbocycles in which the entire ring system (mono- or polycyclic) is saturated. Saturated monocyclic carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc. The fused bicyclic carbocycles are a further subset of the carbocycles in which a C7 to C10 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms (or in the case of spirofused, one carbon atom) are shared by each of the rings in the ring system. A saturated bicyclic carbocycle is one in which both rings are saturated. An unsaturated bicyclic carbocycle is one in which one ring is unsaturated and the other is unsaturated or saturated. Unless otherwise noted, carbocycle is unsubstituted or substituted with C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, aryl, halogen, NH2 or OH. A subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound.
Representative examples of this subset include the following:
Figure imgf000020_0001
Figure imgf000021_0001
Aromatic carbocycles form another subset of the carbocycles. The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems in which the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenyl.
The term "cycloalkyl" means a cyclic ring of an alkane having the specified total ring carbon atoms; for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
The term "heterocycle" (and variations thereof such as "heterocyclic" or
"heterocyclyl") broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 7- to 12-membered bicyclic ring system, wherein each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized. Unless otherwise specified, the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. Unless otherwise specified, when the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
Saturated heterocyclics form a subset of the heterocycles; i.e., the term "saturated heterocyclic" generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term "saturated heterocyclic ring" refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, 1 ,4-dioxanyl, 1 ,4-thioxanyl,
tetrahydropyranyl, tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, and
tetrahy drothiopyrany 1. Heteroaromatics form another subset of the heterocycles; i.e., the term "heteroaromatic" (alternatively "heteroaryl") generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term "heteroaromatic ring" refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12- membered bicyclic aromatic ring, and which consists of carbon atoms and one or more heteroatoms selected from N, O and S. In the case of substituted heteroaryl rings containing at least one nitrogen atom (e.g., pyridine), such substitutions can be those resulting in N-oxide formation. Representative examples of monocyclic heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Examples of bicyclic heteroaromatic rings include
benzotriazolyl, indolyl, benzoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, isoindolyl, indazolyl, quinoxalinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrazolo[3,4-b]pyridine, imidazo[2,l-b](l,3)thiazole, (i.e.,
Figure imgf000022_0001
6-(l-pyrrolyl)-3 -pyridyl, 4-(l-pyrrolyl)phenyl, 4-(pyrid-3-yl)phenyl, and 4- (pyrid-4-yl)phenyl.
Another subset of heterocycles are unsaturated heterocycles in which one or both rings are unsaturated (provided the entire ring system is not aromatic). Representative examples of unsaturated heterocycles include dihydrofuranyl, dihydrothienyl, dihydropyranyl,
dihydroimidazolyl, indolinyl, isoindolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyridinyl, 2,3-dihydrobenzofuranyl, 1,4- benzoxazinyl, 1,3-benzoxazolin l 2 3-dih drobenzo-l -dioxinyl (i.e., eft 0 ), and benzo-
1,3-dioxolyl (i.e.,
Figure imgf000022_0002
). In certain contexts herein, is alternatively referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms. Also included are groups such as chromone and coumarin.
Unless otherwise specifically noted as only unsubstituted or only substituted, cycloalkyl, cycloalkenyl, cycloalkyl, aryl (including phenyl) and heteroaryl groups are unsubstituted or substituted (also referred to as "optionally substituted"). Unless the substituents are specifically provided, substituents for substituted or optionally substituted cycloalkyl, cycloalkenyl, aryl (including phenyl, and as an isolated substituent or as part of a substituent such as in aryloxy and aralkyl), heteroaryl (as an isolated substituent or as part of a substituent such as in heteroaryloxy and heteroaralkyl) are one to three groups independently selected from halogen (or halo), Ci-C6 alkyl optionally substituted with one to five fluorine, NH2, N(Ci-C6 alkyl)2, N02, oxo, CN, N3, -OH, -0(Ci-C6 alkyl) optionally substituted with one to five fluorine, C3-Cio cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (Co-C6 alkyl)S(0)o-2-, aryl-S(0)o-2-, (C0-C6 alkyl)S(0)o-2(Co-C6 alkylene)-, (C0-C6 alkyl)C(0)NH-, H2N-C(NH)-, (Co-C6 alkyl)C(O)-, (C0-C6 alkyl)OC(O)-, (C0-C6alkyl)O(Ci-C6 alkylene)-, (C0-C6 alkyl)- C(0)i-2(Co-C6 alkylene)-, (C0-C6 alkyl)2NC(0)-, (C0-C6 alkyl)OC(0)NH-, aryl, aralkyl, heteroaryl, heteroaralkyl, halo-aryl, halo-aralkyl, halo-heteroaryl, halo-heteroaralkyl, cyano- aryl, cyano-aralkyl, cyano-heteroaryl and cyano-heteroaralkyl.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine
(alternatively referred to as fluoro (F), chloro (CI), bromo (Br), and iodo (I)).
The term "haloalkyl" means alkyl having the specified number of carbon atoms in which from one to all of the hydrogen atoms have been replaced by a halogen atom.
The terms "aralkyl" and "heteroaralkyl" refer to an aryl/heteroaryl linked to the rest of the molecule via a Ci to C4 alkylene.
The term "Co" as employed in expressions such as "C0-6 alkylene" means a direct covalent bond; or when employed in experessions such as "C0-6 alkyl" means hydrogen. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond; for example, in the , wherein s is an integer equal to zero, 1 or 2, the structure is
Figure imgf000023_0001
when s is zero; or it means that the indicated atom is absent; for example -S(0)o- means -S-.
Unless expressly stated to the contrary, an "unsaturated" ring is a partially or fully unsaturated ring. For example, an "unsaturated monocyclic C6 carbocycle" refers to cyclohexene, cyclohexadiene, and benzene.
Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from " 1 to 4 heteroatoms" means the heterocycle can contain 1, 2, 3 or 4 heteroatoms. When any variable occurs more than one time in any constituent or in any formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. For variable definitions containing terms having repeated terms, e.g., (CRiRj)r, where r is the integer 2, Ri is a defined variable, and Rj is a defined variable, the value of Ri may differ in each instance in which it occurs, and the value of Rj may differ in each instance in which it occurs. For example, if Ri and Rj are independently selected from the group consisting of methyl, ethyl, propyl and butyl, then (CRiRj)2 can be
H3CH2C C CH3
H3CH2CH2CH2C- C- CH2CH2CH3
The term
Figure imgf000024_0001
as used hereinabove means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, n- pentyl and n-hexyl. Preferred is (C1-4)alkyl.
The term
Figure imgf000024_0002
means a branched or unbranched alkyl group having 1-5 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and n-pentyl.
The term
Figure imgf000024_0003
as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
The term
Figure imgf000024_0004
means an alkoxy group having 1-3 carbon atoms, the alkyl moiety being branched or unbranched.
The term
Figure imgf000024_0005
means an alkoxycarbonyl group having 1-3 carbon atoms in the alkoxy moiety, the alkoxy moiety having the same meaning as previously defined.
The term (di)(Ci-6)alkylaminocarbonyl means an alkylaminocarbonyl group, the amino group of which is monosubstituted or disubstituted independently with an alkyl group which contains 1-6 carbon atoms and which has the same meaning as previously defined. Preferred alkyl group is (C1-4)alkyl. The term (C3_7)cycloalkyl means a cycloalkyl group having 3-7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 5-6 Carbon atoms are preferred.
The term (C3_5)heterocycloalkyl means a heterocycloalkyl group having 3-5 carbon atoms, including 1-3 heteroatoms selected from N, O and/or S, which may be attached via a nitrogen if feasible, or a carbon atom. Preferred number of heteroatoms is one or two. Most preferred number is one. Preferred heteroatoms are N or O. Most preferred are piperazinyl, tetrahydropyranyl, morpholinyl and pyrrolidinyl.
The term (C2-9)heteroaryl means an aromatic group having 2-9 carbon atoms and 1-3 heteroatoms selected from N, O and S, like imidazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, thiophenyl or furyl, pyrazolyl, isoxazolyl or quinolyl. Preferred number of heteroatoms is one or two. Preferred heteroaryl groups are pyrazolyl, thiophenyl, isoxazolyl, pyridyl and quinolyl. The (C2-5)heteroaryl group may be attached via a carbon atom or a nitrogen, if feasible.
The term (C6-i4)aryl means an aromatic hydrocarbon group having 6-14 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl, anthracyl, More preferred are (C6- io)aryl groups. The most preferred aromatic hydrocarbon group is phenyl.
As used herein, the term "Xa-Xb", shall have the same meaning as the term "Xa-b", wherein X is any atom and a and b are any integers. For example, "C1-C4" shall have the same meaning as "C1-4". Additionally, when referring to a functional group generically, "Ax" shall have the same meaning, and be interchangeable with, "AX", wherein "A" is any atom and "x" or "X" are any integer. For example, "R1" shall have the same meaning, and be
interchangeable with, "Rl".
In the above definitions with multifunctional groups, the attachment point is at the last group.
The term "substituted" means that one or more hydrogens on the designated atom/atoms is/are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. "Stable compound" or "stable structure" is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. When, in the definition of a substituent, is indicated that "all of the alkyl groups" of said substituent are optionally substituted, this also includes the alkyl moiety of an alkoxy group.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The term "effective amount" as used herein, refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof, that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a subject suffering from an RORgammaT-mediated disease or disorder. In the combination therapies of the present invention, as effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.
A "subject" is a human or non-human mammal. In one embodiment, a subject is a human. In another embodiment, a subject is a chimpanzee.
It should be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
The compounds of this invention include the prodrugs, hydrates or solvates of the compounds.
Optical Isomers - Diastereomers - Geometric Isomers - Tautomers
The compounds of Formula I may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers. The present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
When compounds described herein contain olefmic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers.
Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including
carbonyl -CH2C(0)- groups (keto forms) may undergo tautomerism to form hydroxyl - CH=C(OH)- groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are included within the scope of the present invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g.
hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g. substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column. It is also possible that the compounds of Formula I may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
Salts
The term "pharmaceutically acceptable salts" refers to salts prepared from
pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from
pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts prepared from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources. Pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzyl- ethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
The term pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are
commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. They may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like. The acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium carbonate, ammonium (e.g. diethylamine) or lithium hydroxide.
Solvates
The present invention includes within its scope solvates of compounds of Formula I.As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (i.e., a compound of Formula I) or a pharmaceutically acceptable salt thereof and a solvent that does not interfere with the biological activity of the solute. Examples of solvents include, but are not limited to water, ethanol, and acetic acid. When the solvent is water, the solvate is known as hydrate; hydrate includes, but is not limited to, hemi-, mono, sesqui-, di- and trihydrates. The compounds of the invention may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent. One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" may also mean a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non- limiting examples of suitable solvates include ethanolates, methanolates, and the like.
"Hydrate" is a solvate wherein the solvent molecule is H20.
Prodrugs
The present invention includes within its scope the use prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with a compound of formula I or with a compound which may not be a compound of formula I, but which converts to a compound of formula I in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.
A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula I or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Isotopes
In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
Utilities
Compounds of the present invention are inhibitors of Retinoic Acid Receptor-related Orphan Receptor gamma t (RORgammaT), and as such are useful in the treatment of diseases and conditions in which inhibition of RORgammaT is desirable, such as autoimmune and inflammatory diseases and disorders.
Accordingly, another embodiment of the present invention provides a method for treating a disease or condition mediated by RORgammaT in a subject comprising
administering to the subject an amount of a compound having Formula I, la, lb, Ic, Id or Ie or a pharmaceutically acceptable salt or solvate thereof, that is effective for treating the disease or condition mediated by RORgammaT in the subject.
The compounds according to the invention can be used in therapy. A further aspect of the invention resides in the use of compounds according to the invention or a pharmaceutically acceptable salt thereof for the treatment of RORgammaT- mediated diseases or RORgammaT mediated conditions.
Another aspect of the invention resides in the use of compounds or a pharmaceutically acceptable salt thereof having the general formula I for the treatment of autoimmune diseases, in particular those diseases in which Thl7 cells and non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role. These include, but are not limited to, the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.
In another aspect, compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of inflammatory diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to respiratory diseases, osteoarthritis and asthma. Also, compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of infectious diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to mucosal leishmaniasis.
Compounds or a pharmaceutically acceptable salt thereof having the general formula I can also be used for treatment of other diseases in which Thl7 cells and/or non-Thl7 cells, which express Thl7 hallmark cytokines play a prominent role such as, but not limited to Kawasaki disease and Hashimoto's thyroiditis.
In one aspect is the disease or condition is an autoimmune disease or inflammatory disease. The disease or condition includes, but is not limited to, multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
In another aspect, the compounds according to the invention can be used in therapies to treat or prevent multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis and mucosal leishmaniasis.
In another aspect the compounds according to the invention can be used to treat or prevent psoriasis.
In yet another aspect the compounds according to the invention can be used to treat inflammatory bowel disease.
This aspect of the present invention further includes the use of a compound of Formula I, la, lb, Ic, Id or Ie, or a pharmaceutically acceptable salt or solvate thereof, in the
manufacture of a medicament for the treatment of a disease or condition mediated by
RORgammaT.
Route of Administration/Dosage
The compounds of this invention can be administered for the treatment or prevention of afflictions, diseases and illnesses according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravaginal, rectal, intracisternal and parenteral. The term "parenteral" as used herein refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrasternal and intraperitoneal. For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 1.0-2000 milligrams per day. Ordinarily, from 10 to 500 milligrams per day in one or more applications is effective to obtain desired results. These dosages are the effective amounts for the treatment and prevention of afflictions, diseases and illnesses described above, e.g., autoimmune and inflammatory diseases and disorders.
Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, nasal, local, or rectal administration, and the like, all in unit dosage forms for administration. For oral administration, the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
For parenteral administration, the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
Mixed with such pharmaceutically acceptable auxiliaries, e.g. as described in the standard reference, Gennaro, A.R. et al., Remington: The Science and Practice of Pharmacy (20th Edition., Lippincott Williams & Wilkins, 2000, see especially Part 5: Pharmaceutical Manufacturing), the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically acceptable liquids the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing
pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
Pharmaceutical Compositions
Another aspect of the present invention provides pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients. The term "excipient" and "carrier" may be used interchangeably. The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.
The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions. The active ingredient can also be
administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
For administration by inhalation, the compounds of the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons.
For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of Formula I in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
Useful pharmaceutical dosage-forms for administration of the compounds of this invention include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried. A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S. P., and 0.025 milliliters of vanillin.
The same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction with another therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus the term
coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components.
The present invention also relates to a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof having the general formula I in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents. The auxiliaries must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
The invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
The exact dose and regimen of administration of the active ingredient, or a
pharmaceutical composition thereof, may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered. In general parenteral administration requires lower dosages than other methods of administration which are more dependent upon absorption. However, a dosage for humans preferably contains 0.0001-100 mg per kg body weight. The desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day. The dosage as well as the regimen of administration may differ between a female and a male recipient.
Combination Therapy
Compounds of the present invention, and their salts and solvates, and physiologically functional derivatives thereof, may be employed alone or in combination with other therapeutic agents for the treatment of diseases and conditions associated with inappropriate IL-17 pathway activity. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other pharmaceutically active agent. The compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. For the treatment of the inflammatory and autoimmune diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease, SLE, uveitis, atopic dermatitis, COPD, asthma and allergic rhinitis a compound of formula (I) may be combined with one or more other active agents such as: (1) TNF-a inhibitors; (2) non- selective COX-I/COX-2 inhibitors; (3) COX-2 inhibitors; (4) other agents for treatment of inflammatory and autoimmune diseases including glucocorticoids, methotrexate, leflunomide, sulfasalazine, azathioprine, cyclosporin, tacrolimus, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, ciclesonide, hydroxychloroquine, d-penicillamine, aurothiomalate, auranofin or parenteral or oral gold, cyclophosphamide, Lymphostat-B, BAFF/ APRIL inhibitors and CTLA-4-Ig or mimetics thereof; (5) leukotriene biosynthesis inhibitor, 5 -lipoxygenase (5- LO) inhibitor or 5 -lipoxygenase activating protein (FLAP) antagonist; (6) LTD4 receptor antagonist; (7) PDE4 inhibitor; (8) antihistamine HI receptor antagonists; (9) al- and a2- adrenoceptor agonist; (10) anticholinergic agents; (1 1) β-adrenoceptor agonists; (12) insulin- like growth factor type I (IGF-1) mimetic; (13) glucocorticosteroids; (14) kinase inhibitors such as inhibitors of the Janus Kinases (JAK 1 and/or JAK2 and/or JAK 3 and/or TYK2), p38 MAPK and IKK2; ( 15) B-cell targeting biologies such as rituximab; (16) selective costimulation modulators such as abatacept; (17) interleukin inhibitors, such as IL-1 inhibitor anakinra, IL-6 inhibitor tocilizumab, and IL12/IL-23 inhibitor ustekinumab. It could also be combined with anti-IL17 antibodies to obtain additive/synergistic responses for the treatment of inflammatory and autoimmune diseases.
It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention. These combinations are of particular interest in respiratory diseases and are conveniently adapted for inhaled or intranasal delivery.
The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
Preferably, the individual compounds will be administered simultaneously in a combined pharmaceutical composition. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
Accordingly, the pharmaceutical compositions of the present invention include those that also comprise at least one additional therapeutically active agent, in addition to the compound of Formula I, la, lb, Ic, Id or Ie.
The invention further includes a compound of Formula I in combination with one or more other drug(s).
Synthesis Table 1 below lists commercial sources, and previously disclosed synthetic routes, for chemical materials employed in the synthesis of intermediates and examples of the instant invention. This list is not intended to be exhaustive, exclusive, or limiting in any way.
Table 1
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
vV Aobchem
ΗΟ-ΕΪ
OH
Chemmaker
Combi-blocks
Combi-blocks
Anisyn
Anisyn
Figure imgf000043_0001
Alfa
HO-BX F
OH Aldrich
Figure imgf000044_0001
Abbreviations used herein are as follows: Boc: tert-butoxycarbonyl; CDC13:
chloroform-d; DiPEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: N,N-dimethylformamide; Et3N or TEA: triethyl amine; HPLC: high performance liquid chromatography; TFA: trifluoro acetic acid; MS: mass spectrum; (PPh3)4Pd: tetrakis- (triphenylphosphine)palladium(O); THF: tetrahydrofuran; TLC: thin layer chromatography; Si02: silica-gel; DME: dimethoxy ethane; m: molar; t-BuOK; potassium tert-butoxide; APCI- MS: atmospheric pressure chemical ionization mass spectrometry; ESI-MS; electronspray ionization-mass spectroscopy; EtOAc: Ethyl acetate; PE: Petroleum ether; EA: Ethyl acetate; DCM: Dichloro methane; Dppf: 1,1· »Bis(diphenylphosphino)ferrocene; AcOH: Acetic acid; DMAC: N,N -Dimethylacetamide; PYAOP: (7-Azabenzotriazol-l-yloxy)tripyrrolid in ophosphonium hexafluorophosphate; Pd(dppf)Cl2: [l,l'-Bis(diphenylphosphino)
ferrocene ]dichloropalladium (II); BnBr: Benzyl bromide; DAST: (Diethylamino)sulfur trifluoride; Ac20: Acetic an hydride; LiHMDS: Lithium bis(trimethylsilyl)amide; PhNTf2: N- Phenyl-bis(trifluoro methanesulfonimide); S-Phos: 2-Dicyclohexylphosphino-2',6'- dimethoxybiphenyl; X-Phos: 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; CPME: Cyclopentyl methyl ether.
Intermediates
Example i-1: Preparation of methyl 2-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzoate (i-1) Scheme i-1.
Figure imgf000045_0001
i-1 i) Preparation of methyl 4-(benzyloxy)-2-hydroxybenzoate (i-lb). To a solution of methyl 2,4-dihydroxybenzoate (i-la) (1.68 g, 10 mmol) in acetone (30 mL) was added K2C03 (2.76 g, 20 mmol). The mixture was stirred at rt for 5 h, followed by the addition of BnBr (1.88 g, 11 mmol). The mixture was heated at 60 °C for 24 h. The reaction mixture was cooled down, filtered. The filtrate was concentrated to afford the title compound. LCMS (ESI) calc'd for C15H14O4 [M+H]+: 259.1, found: 259.1. ii) Preparation of methyl 4-(benzyloxy)-2-(trifluoromethylsulfonyloxy)benzoate (i-lc).
To a solution of methyl 4-(benzyloxy)-2-hydroxybenzoate (i-lb) (1.1 g, 4.26 mmol) in THF (20 ml) at -78 °C was added LiHMDS (1M in THF, 5.1 ml, 5.1 mmol) dropwise. Then the mixture was warmed up to -40 °C and stirred at this temperature for 3 h. PhNTf2 (1.52 g, 4.26 mmol) was added, and the mixture was stirred at rt for 24 h. The mixture was then diluted with H20, and extracted with EtOAc. The organic layer was dried, concentrated, and purified by flash chromatography (PE/EA=10: 1) to afford the title compound. LCMS (ESI) calc'd for CieHisFsOeS [M+H]+: 391 , found: 391. iii) Preparation of methyl 4-(benzyloxy)-2-(prop-l-en-2-yl)benzoate (i-ld). Methyl 4- (benzyloxy)-2-(trifluoromethylsulfonyloxy)benzoate (i-lc) (6.8 g, 17.4 mmol), 4,4,5,5- tetramethyl-2-(prop-l-en-2-yl)-l ,3,2-dioxaborolane (2.9 g, 17.4 mmol), Pd(OAc)2 (195 mg, 0.87 mmol), S-Phos (71 mg, 0.174 mmol) and K3PO4 (1 1 g, 52 mmol) were mixed in THF (70 ml). The mixture was stirred at 75 °C for 24 h. The mixture was diluted with H20, and extracted with EtOAc. The combined organics were dried and concentrated. The residue was purified by flash chromatography (PE/EA=10: 1) to afford the title compound. LCMS (ESI) calc'd for Ci8Hi803 [M+H]+: 391 , found: 391. iv) Preparation of methyl 4-hydroxy-2-isopropylbenzoate (i-le). To a solution of methyl 4-(benzyloxy)-2-(prop-l-en-2-yl)benzoate (i-ld) (4.6 g, 16.3 mmol) in methanol (100ml) was added Pd/C (0.46 g). The mixture was stirred at rt under H2 atmosphere for 24 h. Then the mixture was filtered, and the filtrate was concentrated to afford the title compound. LCMS (ESI) calc'd for CiiHM03 [M+H]+: 195.1 , found: 195.1. v) Preparation of methyl 2-isopropyl-4-(trifluoromethylsulfonyloxy)benzoate (i-lf). To a solution of methyl 4-hydroxy-2-isopropylbenzoate (i-le) (2.45 g, 12.6 mmol) in THF (100 ml) at -78 °C was added LiHMDS (1M in THF, 15 ml, 15 mmol) dropwise. Then the mixture was warmed up to -40 °C and stirred for 3 h. PhNTf2 (4.5 g, 12.6 mmol) was added and the mixture was stirred at rt for 24 h. The reaction mixture was diluted with H20 and extracted with EtOAc. The organic layer was dried and concentrated. The residue was purified by flash chromatography (PE/EA=8: 1) to afford the title compound. LCMS (ESI) calc'd for Ci2Hi3F305S [M+H]+: 327, found: 327. vi) Preparation of methyl 2-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2- yl)benzoate (i-1). Methyl 2-isopropyl-4-(trifluoromethylsulfonyloxy)benzoate (i-lf) (1.5 g, 4.6 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l ,3,2-dioxaborolane) (1.75 g, 6.9 mmol), Pd(dppf)Cl2.CH2Cl2 (188 mg, 0.23 mmol), dppf (102 mg, 0.184 mmol) and KOAc (1.13 g, 11.5 mmol) were mixed in 1,4-dioxane (35 ml). The mixture was stirred at 80 °C for 24 h. The mixture was then cooled down and concentrated under reduced pressure. The residue was diluted with H20, extracted with EtOAc. The combined organics were dried and concentrated. The residue was purified by flash chromatography (PE/EA=10:1) to afford the title compound. LCMS (ESI) calc'd for Ci7H25B04 [M+H]+: 305.2, found: 305.2.
Example i-2: Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)benzoate (i-2)
Scheme i-2.
Figure imgf000047_0001
-2a -2b i) Preparation of methyl 4-bromo-2-fluoro-5-methylbenzoate (i-2b). To a solution of 4- bromo-2-fluoro-5-methylbenzoic acid (i-2a) (1.87 g, 8 mmol) in CH3OH (50 mL) at 0 °C was added SOCl2 (6 mL, 80 mmol) dropwise. Then the mixture was heated to 80 °C for 2 h. The solvent was removed in vacuo and the residue was diluted with EtOAc and washed with H20, brine, dried over anhydrous Na2S04, and concentrated. The resulting crude solid was washed with PE to give the title compound as a yellow solid. 1H NMR (400 MHz, CDC13) δ 7.80 (1H, d), 7.37 (1H, d), 3.92 (3H, s), 2.39 (3H, s). ii) Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan- 2-yl)benzoate (i-2). To a flask was added compound (i-2b) (830 mg, 3.3 mmol), compound (i-2c) (915 mg, 3.6 mmol), dppf (25 mg, 0.132 mmol), Pd(dppf)Cl2*CH2Cl2 (134 mg, 0.165 mmol) and 1,4-dioxane (20 mL). The reaction mixture was heated at 80 °C for 2 h. The mixture was diluted with H20, and the organic layer was separated. The aqueous layer was extracted with CH2CI2. The combined organics were washed with H20 and brine, dried over Na2S04, and concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for C15H20BFO4 [M+H]+: 295.1, found: 295.1.
Example i-3: Preparation of methyl 3,5-dimethoxy-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzoate (i-3)
Figure imgf000048_0001
i) Preparation of methyl 4-bromo-3,5-dimethoxybenzoate (i-3b).
Prepared following a similar procedure of compound i-2b
LCMS (ESI) calc'd for Ci0HnBrO [M+H]+: 275.1, found: 275.1. ii) Preparation of methyl 3,5-dimethoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2- yl)benzoate (i-3)
Prepared following a similar procedure of compound i-2
LCMS (ESI) calc'd for CieifeBOe [M+H]+: 323.2, found: 323.2.
Example i-4: Preparation of methyl 2,5-difluoro-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzoate (i-4)
Figure imgf000049_0001
i) Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2- yl)benzoate (i-4). To a flask was added compound (i-4a) (412 mg, 2.0 mmol), compound (i- 2c) (1.52 g, 6 mmol), X-Phos (95 mg, 0.2 mmol), Pd(OAc)2 (44 mg, 0.2 mmol) and CPME (20 mL). The reaction mixture was heated at 85 °C for 2 h. The mixture was then cooled down, diluted with H20, and the organic layer was separated. The aqueous layer was extracted with Et20. The combined organics were washed with H20 and brine, dried over Na2S04, and concentrated. The residue was purified by flash chromatography (DCM) to afford the title compound. LCMS (ESI) calc'd for Ci4Hi7BF204 [M+H]+: 299.1, found: 299.1.
Example i-5: Preparation of 3-fluoro-5-methoxy-4-(methoxycarbonyl)phenyl boronic acid (i-5)
Figure imgf000049_0002
i-5b i-5c i) Preparation of methyl 4-bromo-2,6-difluorobenzoate (i-5b)
Prepared following a similar procedure of compound i-2b
LCMS (ESI) calc'd for C8H5BrF202 [M+H]+: 250.9, Found: 250.9. ii) Preparation of methyl 4-bromo-2-fluoro-6-methoxybenzoate (i-5c). To a solution of compound (i-5b) (827 mg, 3.3 mmol) in DMF (20 mL) at 0 °C was added a solution of sodium methoxide (25% in MeOH, 0.75 mL, 3.3 mmol). The reaction mixture was stirred at 0 °C for 10 min and then at rt for 30 min. The mixture was then brought back to 0 °C and quenched with EtOAc and 1M HC1. The organic layer was separated and the aqueous phase was extracted with EtOAc. The combined organics were dried over Na2S04 and concentrated. The crude oil was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for C9H8BrF03 [M+H]+: 263.0, found: 263.0; 1H NMR (400 MHz, CDC13) δ 6.98 (1H, t), 6.91 (1H, q), 3.76 (3H, s), 3.74 (3H, s). ii) Preparation of 3-fluoro-5-methoxy-4-(methoxycarbonyl)phenylboronic acid (i-5)
Prepared following a similar procedure of compound i-2
LCMS (ESI) calc'd for C9Hi0BFO5 [M+H]+: 229.1 , found: 229.1.
Example i-6: Preparation of 4-borono-3,6-difluoro-2-methoxybenzoic acid (i-6)
Scheme i-6.
Figure imgf000050_0001
i) Preparation of 3,6-difluoro-2-methoxybenzoic acid (i-6b).
A solution of 1 ,4-difluoro-2-methoxybenzene (i-6a) (2.88 g , 20 mmol) in THF (5 mL) was added to a solution of LDA freshly prepared from n-BuLi (10M solution in hexane, 2.2 mL, 22 mmol) and diisopropylamine (2.28 g , 22.8 mmol) in THF (20 mL) at -60 °C. After 30min, a freshly prepared solution of C02 in diethyl ether (20 mL) was quickly added. Then aq. H2S04 was added, and the resulting precipitate was collected and washed with H20, and dried to give the title compound (i-6b) as white crystals. LCMS (ESI) calc'd for C8H6F203 [M+H]+: 189, found: 189. ii) Preparation of 4-borono-3,6-difluoro-2-methoxybenzoic acid (i-6). To a solution of 3,6-difluoro-2-methoxybenzoic acid (i-6b) (0.94 g , 5 mmol) in THF (5 mL) at -70 °C was added a solution of LDA [freshly prepared from diisopropylamine (1.51 g, 15 mmol) and n-BuLi (10M solution in hexane, 1.5 mL, 15mol) in THF (15 mL). The resultant solution was stirred for 15 mins, followed by the addition of B(OEt)3 (1.46 g , 10 mmol). The mixture was stirred for 15mins and then hydrolyzed with dilute aq. H2SO4. The organic phase was separated and the aqueous layer was extracted with Et20. The combined organics were concentrated and the residue solid was washed with H20 and hexane, dried to give the title compound as white crystals. LCMS (ESI) calc'd for C8H7BF205 [M+H]+: 233, found: 233.
Example i-7: methyl 5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2-yl)benzoate (i-7)
Scheme i-7.
Figure imgf000051_0001
i-7 i) Preparation of 4-bromo-2,5-difluorobenzoic acid (i-7b)
To a solution of l,4-dibromo-2,5-difluorobenzene (i-7a) (1.1 g , 4 mmol) in Et20 (10 mL) at - 78 °C was added n-BuLi (2.5M in hexane, 1.6 mL, 4 mmol) dropwise. The mixture was stirred for 30 min at -78 °C and then quenched with an excess of freshly crushed dry ice. After 15 min, the mixture was brought to rt and diluted with H20. The aqueous layer was separated, and the organic layer was extracted with 10% aq. Na2C03. The combined aqueous layers were acidified with 1M HC1 and extracted with EtOAc. The combined organic layers were dried with Na2S04 and concentrated to give the title compound. LCMS (ESI) calc'd for C7H3BrF202 [M+H]+: 237, found: 237. ii) Preparation of methyl 4-bromo-2,5-difluorobenzoate (i-7c)
A mixture of 4-bromo-2,5-difluorobenzoic acid (i-7b) (0.48 g, 2 mmol) and methanol (10 mL, saturated with gaseous HC1 ) was heated at 65 °C for 2 h. The mixture was concentrated.
Then MeOH was added and the mixture was concentrated again. The residue was purified by flash chromatography (Pentane/EtOAc=4: l) to give the title compound. LCMS (ESI) calc'd for C8H5BrF202 [M+H]+: 251, found: 251. iii) Preparation of methyl 4-bromo-5-fluoro-2-methoxybenzoate (i-7d)
To a solution of methyl 4-bromo-2,5-difluorobenzoate (i-7c) (0.5 g, 2 mmol) in DMF (5 mL) at 0 °C was added NaOMe (25% in MeOH, 0.45 mL, 2 mmol). The reaction mixture was stirred at 0 °C for 10 min and then at rt for 30min. The mixture was then brought back to 0 °C and quenched with EtOAc and 1M HC1. The organic layer was separated, and the aqueous phase was extracted with EtOAc, dried over Na2S04, concentrated and purified by flash chromatography (Pentane/EtOAc=9: l) to give the title compound. LCMS (ESI) calc'd for C9H8BrF03 [M+H]+: 263, found: 263 iv) Preparation of methyl5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan- 2-yl)benzoate (i-7)
A mixture of Bis(pinacolato)diboron (0.72 g, 2.86 mmol), Pd(OAc)2 (50mg), X-Phos (100 mg), methyl 4-bromo-5-fluoro-2-methoxybenzoate (i-7d) (0.5 g, 1.9 mmol), and KOAc (100 mg) in DMAC (20 mL) were heated at 80 °C for 24 h. The mixture was then cooled down, diluted with EtOAc and H 0. The organic layer was separated and the aqueous layer was extracted with EtOAc. The organics were combined, dried, concentrated and purified by flash chromatography (Pentane/EtOAc=10: l) to give the title compound. LCMS (ESI) calc'd for Ci5H2oBF05 [M+H]+: 311, found: 311
Example i-8: Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(3-iodo-6- (methoxymethyl)-lH-indazol-l-yl)methanone (i-8)
Figure imgf000053_0001
i) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(6-(hydroxymethyl)-3-iodo- 1H- indazol-l-yl)methanone (i-8b). To a solution of compound (i-8a) (prepared following the procedure of Scheme D) (175 mg, 0.35 mmol) in THF (20 mL) was added BH3-THF (1.75 mL, 1.75 mmol) and the mixture was re fluxed for 12 h. The mixture was cooled down and quenched with excess MeOH. The mixture was concentrated to give the title compound. LCMS (ESI) calc'd for Ci6H9ClF3IN202 [M+H]+: 480.9, found: 480.9. ii) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(3-iodo-6-(methoxy methyl)-/H- indazol-l-yl)methanone (i-8). To a mixture of (i-8b) (0.2 g, 0.416 mmol) in THF (5 mL) was added NaH (25 mg, 0.62 mmol) and the mixture was stirred at room temperature for 30 min. Then iodomethane (0.1 mL, 0.83 mmol) was added dropwise. The reaction mixture was stirred at rt for 24 h. Ammonium Hydroxide (5 mL) was added to quench the reaction. The solvent was removed under reduced pressure and the residue was diluted with aq. NH4CL. The mixture was extracted with EtOAc, and the combined organics were washed with brine, dried over anhydrous Na2S04 and concentrated. The residue was purified by prep-TLC (PE:EA 4: 1) to provide the title compound as a pale yellow solid. LCMS (ESI) calc'd for Ci7HiiClF3rN202 [M+H]+: 495, found: 495.
Method for Preparing Compounds of the Invention
Methods for preparing the compounds of this invention are illustrated in the following schemes. Other synthetic protocols will be readily apparent to those skilled in the art. The examples illustrate the preparation of the compounds of Formula I and as such are not to be considered as limiting the invention set forth in the claims appended hereto. Unless otherwise indicated, all variables are as previously defined.
Figure imgf000054_0001
The heterocyclic derivatives of Formula I, wherein A4 to A7, R1, R2, R3, X and Y are as previously defined, can be prepared from compounds II. Palladium catalyzed Suzuki- Miyaura arylation of compounds II using appropriately substituted phenylboronic acids Ill-a (corresponding boronic esters Ill-b may also be used) directly affords the desired compounds I. In a typical procedure, a mixture of compound II, a palladium catalyst (e.g. Pd(PPh3)4), base (e.g. aqueous NaOH, K2C03 or the like) and an aryl boronic acid of general Formula III- a or aryl boronic ester of general formula Ill-b in a suitable solvent such as dioxane or toluene/EtOH, is heated under an atmosphere of nitrogen under microwave irradiation or using conventional heating.
Figure imgf000054_0002
Alternatively, compound I may be obtained from compounds of Formula IV, in which FG is a functional group (e.g. ester, cyano, protected tetrazole) that can be easily converted to groups defined for R2. Non limiting examples of suitable functional groups in compounds IV are a tert-butyl ester or methyl ester or a tetrazole, containing an acid labile group such as a? ra-methoxy benzyl protecting group, which can be treated with acid or base to afford compounds of Formula I-a or I-b in which R2 is carboxyl or 5-tetrazolyl, respectively.
O
u
R ^CI
or
Figure imgf000055_0001
VI V: Hal = Br, CI , I ll-a: X = S02
I I-b: X = CO
Hal = Br, CI, I
Compounds II are prepared by straightforward acylation or sulfonylation of compounds V. For example, treatment of compounds V with a strong base (such as potassium tert- butoxide or NaH) and the appropriately substituted sulfonyl chlorides in a suitable solvent such as DMF or THF will give compounds Il-a in which X = S02. Alternatively, treatment of V with sulfonyl chlorides and a tertiary amine base (e.g. DiPEA or triethylamine) in a solvent such as dichloromethane can also give compounds Il-a. Treatment of V with acyl chlorides in pyridine or Et3N will yield compounds Il-b, in which X = CO. In case the acid chlorides are not available, they can be easily prepared from the corresponding carboxylic acids using known methods (e.g. treatment with SOCl2 or similar reagents). Compounds V are commercially available or prepared by methods know in the art, such as halogenation of compounds VI. Compounds VI are also commercially available or easily prepared by standard organic synthesis techniques.
Figure imgf000056_0001
Compounds IV can be prepared in the same way as compounds I, by Suzuki-Miyaura reaction between compounds of general Formula II and an appropriately substituted arylboronic acid or ester.
Figure imgf000056_0002
VII: Hal = Br, CI, I Ν, Μ I V-U. A - U
V l " FG = Functional Group
Alternatively, a Suzuki reaction on compounds VII (obtained by Boc-protection of compounds V) will give compounds VIII (in most cases the Boc-group is cleaved under the reaction conditions, although a separate deprotection may be necessary). Now, acylation or sulfonylation as described for the conversion of V to II, yields compounds IV. The functional group (FG in formula IV) may be a tert-butyl ester, or a /? ra-methoxy benzyl protected tetrazole, which after treatment with trifluoro acetic acid will give a carboxylate or 5- tetrazolyl, respectively, as required for compounds I. Finally, a Suzuki reaction on unprotected compounds V, may also directly lead to compounds VIII.
The invention is illustrated by the following examples.
General The following procedure was used for Examples 1-23. 1H NMR spectra were recorded on a Bruker spectrometer (400 MHz) with deuterochloroform as the solvent unless stated otherwise. Chemical shifts are reported as δ values (parts per million) relative to
tetramethylsilane as an internal standard.
MS: Electro Spray spectra were recorded on the Applied Biosystems API- 165 single quad MS in alternating positive and negative ion mode using Flow Injection. The mass range was 120-2000 Da and scanned with a step rate of 0.2 Da. and the capillary voltage was set to 5000 V. N2-gas was used for nebulasation.
LC-MS spectrometer (Waters) Detector: PDA (200-320 nm), Mass detector: ZQ
Eluens : A: acetonitrile with 0.05% trifluoroacetic acid , B: acetronitrile / water = 1/9 (v/v) with 0.05% trifluoroacetic acid
Column 1 : Chromolith Performance, RP-18e, 4.6x100 mm,
Gradient method: Flow: 4 mL/min
Time (min) A (%)
0,0 100 0
3.60 0 100
4.00 0 100
4.05 100 0
6.00 100 0
Column 2: XBridge CI 8, 3.5μιη, 4.6x20mm
Gradient method: Flow: 4 ml/min
Time (min.) A (%)
0.0 100 0
1.60 0 100
3.10 0 100
3.20 100 0
5.00 100 0
UPLC : Water acquity UPLC system; Column : BEH C18 1.7 μιη, 2.1 x 100 mm, Detector: PDA (200-320 nm), Mass detector: SQD
Eluens : A: acetonitrile with 0.035% trifluoroacetic acid , B: acetronitrile / water = 1/9 (v/v) with 0.035% trifluoroacetic acid Method 60 100 Method 40 80 Method 0 60
Flow: 0.75 mL/min Flow: 0.65 mL/min Flow: 0.60 mL/min Time (min)A (%) B (%) A (%) B (%) A (%) B
(%)
0.0 40 60 60 40 100 0
3.00 0 100 20 80 40 60
3.20 0 100 0 100 0 100
3.69 0 100 0 100 0 100
3.70 40 60 60 40 100 0
All target compounds were characterized and determined as at least >95 % pure by 1H NMR, MS and analyticakl HPLC.
Examples
Example 1
Figure imgf000058_0001
4-(l-(2,6-dichlorobenzoyl H-indazol-3-yl)benzoic acid
i) A solution of 3-bromo-4-azaindole (100 mg, 0.508 mmol) and 2,6-dichlorobenzoyl chloride (159 mg, 0.761 mmol) in 4 ml of pyridine was stirred for 1 h at 150 °C in a microwave reactor. After cooling to room temperature the reaction mixture was diluted with water and the product was extracted into CH2CI2. The organic layer was washed with water, dried over a phase separation filter and concentrated under reduced pressure. The residue was purified on S1O2, using 10% ethylacetate in heptane as the eluent, to give (3-bromo-7H-indazol- 1 -yl)(2,6- dichlorophenvDmethanone (140 mg) as a yellow solid.
ii) To a microwave reaction vial were added the product obtained in the previous step (53 mg, 0.143 mmol) in 2 ml dioxane, 4-(tert-butoxycarbonyl)phenylboronic acid (47.7 mg, 0.215 mmol) and a 2M aqueous solution of sodium carbonate (0.286 ml, 0.573 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (8.28 mg, 7.16 μιηοΐ) was added and the reaction mixture was stirred for 30 minutes at 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and washed with water, brine and dried over magnesium sulfate.
After filtration the solvent was evaporated under reduced pressure and the desired product, tert-butyl 4-(l-(2,6-dichlorobenzoyl)-7H-indazol-3-yl)benzoate, was obtained as a yellow solid (90 mg). The product was used in the next step without further purification,
iii) A solution of the product obtained in the previous step (90 mg, 0.22 mmol) and trifluoroacetic acid (5 ml, 67.3 mmol) in 20 ml CH2CI2 was stirred for lh at room temperature After completion, the reaction mixture was concentrated under reduced pressure and the residue was purified on S1O2, using 10% ethylacetate in heptane as the eluent to give the title compound 4-(l-(2,6-dichlorobenzoyl)-7H-indazol-3-yl)benzoic acid as a white solid (50 mg). ESI MS = m/z 411 [M+H]+
Example 2
Following a procedure analogous to that described in Example 1, starting from 3-bromo-5- fluoro-iH-indazole, the following compound was prepared.
4-(l-(2,6-dichlorobenzoyl)-5-fluoro-7H-indazol-3-yl)benzoic acid
ESI MS = m/z 429 [M+H]+
Figure imgf000059_0001
Example 3
Following a procedure analogous to that described in Example 1, starting from 3-bromo-7- fluoro-iH-indazole, the following compound was prepared.
4-(l-(2,6-dichlorobenzoyl)-7-fluoro-7H-indazol-3-yl)benzoic acid
Figure imgf000060_0001
ESI MS = m/z 429 [M+H]+
Example 4
Following a procedure analogous to that described in Example 1, starting from 3-bromo-4- fluoro-iH-indazole, the following compound was prepared.
4-(l-(2,6-dichlorobenzoyl)-4-fluoro-7H-indazol-3-yl)benzoic acid
Figure imgf000060_0002
ESI MS = m/z 429 [M+H]+
Example 5
Following a procedure analogous to that described in Example 1, starting from 3-bromo-6- fluoro-iH-indazole, the following compound was prepared.
4-(l-(2,6-dichlorobenzoyl)-6-fluoro-7H-indazol-3-yl)benzoic acid
ESI MS = m/z 429 [M+H]+
Example 6
Following a procedure analogous to that described in Example 1, starting from 3-bromo-iH- pyrazolo[4,3-b]pyridine, the following compounds were prepared.
6A: 4-(l-(2,6-dichlorobenzoyl)-7H-pyrazolo[4,3-blpyridin-3-yl)benzoic acid
ESI MS = m/z 412 [M+H]+
Figure imgf000061_0001
6B: 4-(l-(2-(trifluoromethyl)benzoyl)-7H-pyrazolo[4,3-blpyridin-3-yl)benzoic acid
= m/z 412 [M+H]+
Figure imgf000061_0002
Example 7
Following a procedure analogous to that described in Example 1, starting from 3-bromo-iH- pyrrolo[3,2-b]pyridine, the following compound was prepared.
4-(l-(2,6-dichlorobenzoyl)-7H-pyrrolo[3,2-blpyridin-3-yl)benzoic acid
= m/z 412 [M+H]+
Figure imgf000061_0003
Example 8
Following a procedure analogous to that described in Example 1, starting from 3-bromo-iH- pyrazolo[4,3-c]pyridinei the following compound was prepared. 4-(l-(2,6-dichlorobenzoyl)-7H-pyrazolo[4,3-clpyridin-3-yl)benzoic acid
= m/z 412 [M+H]+
Figure imgf000062_0001
Figure imgf000062_0002
1,1,1 ,3 ,3-hexafluoro-2-(4-(l -(2-(trifluorometliyl)plienylsulfonyl)-iH-indazol-3- yl)phenyl)propan-2-ol
i) To a suspension of 3-bromoindazole (500 mg, 2.54 mmol) in 8 ml CH2CI2 was added triethyl amine (1.06 ml, 7.61 mmol) at room temperature. To this yellow solution was added 2-(trifluoromethyl)benzenesulfonyl chloride (0.392 ml, 2.54 mmol) and the reaction mixture was stirred for 3 h at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was purified on Si02 using 5% to 20% ethyl acetate in heptane to give 3-bromo-l-(2-(trifluoromethyl)phenylsulfonyl)-iH-indazole (894 mg)
ii) Following a procedure analogous to that described in Example 1, step ii, using 1,1,1,3,3,3- hexafluoro-2-(4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol as the boronic ester, the title compound 1,1,1 ,3 ,3 ,3-hexafluoro-2-(4-(l -(2-
(trifluoromethyl)phenylsulfonyl H-indazol-3 -yl)phenyl)propan-2-ol was prepared (9 mg). ESI MS = m/z 569 [M+H]+ Example 10
Figure imgf000063_0001
4-(l -(2-(trifluoromethyl)benzoyl)-7H-indazol-3-yl)benzoic acid
i) To a mixture of tert-butyl 3-bromo-iH-indazole-l-carboxylate (5 g, 16.83 mmol,) and 4- (tert-butoxycarbonyl)phenylboronic acid (4.52 g, 20.36 mmol) in 30 ml of dioxane and 30 ml water was added sodium carbonate (50.5 mmol, 5.35 g). The mixture was purged with N2 and subsequently, Pd(PPh3)4 (0.486 g , 0.421 mmol) was added. The reaction mixture was heated to 100°C overnight under a nitrogen atmosphere.
After cooling to room temperature, the reaction mixture was diluted with water and the product was extracted into ethyl acetate. The combined organic layers were washed with water, brine and dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure and the residue was purified on Si02, using 0% to 25 % ethylacetate in heptane as the eluent, to give tert-butyl 4-(7H-indazol-3-yl)benzoate as a yellow solid. ii) To a solution of tert-butyl 4-(7H-indazol-3-yl)benzoate (40 mg, 0.136 mmol) in 1 ml of pyridine was added 2-(trifluoromethyl)benzoyl chloride (356 mg, 1.699 mmol).
The reaction mixture was stirred at 150 °C in a microwave reactor for lh
After cooling, water was added and the product was extracted into ethylacetate. The organic layer was washed with water, brine and dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure and the residue was purified on Si02, using 3% to 20% ethylacetate in heptane as the eluent, to give tert-butyl 4-(l-(2- (trifluoromethyl)benzoyl)-7H-indazol-3-yl)benzoate as a white solid.
iii) A solution of the compound obtained in the previous step (19.4 mg, 0.042 mmol) and trifluoroacetic acid (0.5 ml, 6.73 mmol,) in 2 ml CH2C12 was stirred for lh at room temperature. After the reaction was complete the reaction mixture was concentrated under reduced pressure to give the title compound 4-(l-(2-(trifluoromethyl)benzoyl)-7H-indazol-3- vDbenzoic acid as a light yellow solid.
ESI MS = m/z 411 [M+H]+
Example 11
Following a procedure analogous to that described in Example 10, the following compounds were prepared.
11 A: 4-(l-(3,5-dichloroisonicotinoyl)-7H-indazol-3-yl)benzoic acid
ESI MS = m/z 412 [M+H]+
Figure imgf000064_0001
11B: 4-(l-(2-bromobenzoyl)-7H-indazol-3-yl)benzoic acid
= m/z 421/423 [M+H]+
Figure imgf000064_0002
11C: 4-(l-(2-(methoxycarbonyl)benzoyl)-7H-indazol-3-yl)benzoic acid
ESI MS = m/z 401 [M+H]+
Figure imgf000065_0001
11D: 4-(l -(cyclohexanecarbonyl)-iH-indazol-3-yl)benzoic acid
= m/z 349 [M+H]+
Figure imgf000065_0002
HE: 4-(l-(2-bromo-6-chlorobenzoyl)-7H-indazol-3-yl)benzoic acid
= m/z 457 [M+H]+
11F: 4-(l-(2-fluoro-6-(trifluoromethyl)benzoyl)-7H-indazol-3-yl)benzoic acid ESI MS = m/z 429 [M+H]+
Figure imgf000066_0001
11G: 4-(l-(2-fluoro-6-methoxybenzoyl)-7H-indazol-3-yl)benzoic acid = m/z 391 [M+H]+
Figure imgf000066_0002
11H: 4-(l-(2,4,6-trichlorobenzoyl)-7H-indazol-3-yl)benzoic acid = m/z 445 / 447 [M+H]+
Figure imgf000066_0003
111: 4-(l-(2,6-dimethylbenzoyl)-7H-indazol-3-yl)benzoic acid
= m/z 371 [M+H]+
Figure imgf000066_0004
11J: 4-(l-(2-ethoxybenzoyl)-7H-indazol-3-yl)benzoic acid = m/z 387 [M+H]
Figure imgf000067_0001
UK: 4-(l-(2,3-dichlorobenzoyl)-7H-indazol-3-vnbenzoic acid
= m/z 411 [M+H]+
Figure imgf000067_0002
11L: 4-(l-(2-chlorobenzoyl)-7H-indazol-3-vnbenzoic acid
ESI MS = m/z 377 [M+H]+
Figure imgf000067_0003
11M: 4-( 1 -( 2-chloro-6-( trifluoromethynbenzoyl - 7H-indazol-3 -vDbenzoic acid ESI MS = m/z 445 [M+H]+
Figure imgf000068_0001
UN: 4-(l-(2-methyl-6-nitrobenzoyl)-7H-indazol-3-yl)benzoic acid
ESI MS = m/z 402 [M+H]+
Figure imgf000068_0002
Example 12
4-(l-(2-(trifluorometliyl)plienylsulfonyl)-iH-indazol-3-yl)benzoic acid
Figure imgf000068_0003
i) To a solution of tert-butyl 4-(7H-indazol-3-yl)benzoate, Example 10, step i, (58 mg, 0.197 mmol) in 2 ml CH2CI2 were added triethyl amine (60 mg, 0.592 mmol) and 2-
(trifluoromethyl)benzenesulfonyl chloride (48 mg, 0.197 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was directly purified on Si02 using 0% to 50% ethyl acetate in heptane as the eluent to give tert-butyl 4-(l-(2- (trifluoromethyl)phenylsulfonyl)-iH-indazol-3-yl)benzoate )102 mg) as a clear oil. ii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-( 1 -(2-(trifluoromethvnphenylsulfonyl -iH-indazol-3-yl)benzoic acid, was prepapred (28 mg)
ESI MS = m/z 447 [M+H]+
Example 13
Following a procedure analogous to that described in Example 11, the following compounds were prepared.
13A: 4-(l -(quinolin-8-ylsulfonyl)-iH-indazol-3-yl)benzoic acid
ESI MS = m/z 429 [M+H]+
Figure imgf000069_0001
13B: 4-(l-(2-bromophenylsulfonyl)-7H-indazol-3-vnbenzoic acid
ESI MS = m/z 457/459 [M+H]+
Figure imgf000069_0002
13C: 4-(l-(2,5-dichlorophenylsulfonvn- H-indazol-3-yl)benzoic acid
ESI MS = m/z 447 [M+H]+
Figure imgf000070_0001
D: 4-(l-(3-chloro-2-methylphenylsulfonyl)-iH-indazol-3-vnbenzoic acid I MS = m/z 427 [M+H]+
Figure imgf000070_0002
E: 4-(l-(2,3-dichlorophenylsulfonyl)-7H-indazol-3-yl)benzoic acid I MS = m/z 447 [M+H]+
Figure imgf000070_0003
F: 4-(l-(2.3,4-trichlorophenylsulfonvn-HJ-indazol-3-yl)benzoic acid I MS = nVz 481/483 [M+H]+
Figure imgf000071_0001
Example 14
Figure imgf000071_0002
4-(l -(2-cyanophenylsulfonyl H-indazol-3-yl)benzoic acid
i) To a solution of 3-bromo-iH-indazole (200 mg, 1.02 mmol) in 2 ml CH2CI2 was added triethylamine (308 mg, 3.05 mmol) and 2-cyanobenzene-l-sulfonyl chloride (205 mg, 1.02 mmol). The reaction mixture was stirred overnight at room temperature. After completion the reaction mixture was concentrated under reduced pressure and the product was purified on Si02 using 0% to 50% ethylacetate in heptane as the eluent to give 4-(\-(2- cyanophenylsulfonyl H-indazol-3-yl)benzoic acid (360 mg) as a yellow solid.
ii) To a microwave reaction vial were added the product obtained in the previous step (50 mg, 0.138 mmol) in 2 ml toluene and 0.5 ml ethanol, 4-(tert-butoxycarbonyl)phenylboronic acid (50 mg, 0.166 mmol) and a 2M aqueous solution of potassium carbonate (0.345 ml, 0.690 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (3.99 mg) was added and the reaction mixture was stirred for 30 minutes at 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with water and product was extracted into ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate. After filtration the solvent was evaporated under reduced pressure and the product was purified on Si02 using 0% to 50% ethylacetate in heptane as the eluent to give the desired product, tert-butyl 4-(l-(2-cvanophenylsulfonyl)-lH-indazol-3-yl)benzoate (12 mg).
iii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(l-(2-cyanophenylsulfonyl)-iH-indazol-3-yl)benzoic acid, was prepapred (13 mg)
ESI MS = m/z 404 [M+H]+ Example 15
Following a procedure analogous to that described in Example 14, the following compounds were prepared.
15 A: 4-(l-(2-(trifluoromethoxy)phenylsulfonyl)-iH-indazol-3-yl)benzoic acid
ESI MS = m/z 463 [M+H]+
Figure imgf000072_0001
15B: 4-( 1 -(naphthalen- 1 -ylsulfonyl)-iH-indazol-3-yl)benzoic acid
ESI MS = m/z 429 [M+H]+
Figure imgf000072_0002
15C: 4-(l-(2,6-dichlorophenylsulfonyl)-iH-indazol-3-yl)benzoic acid
ESI MS = m/z 447 [M+H]+
Figure imgf000073_0001
5D: 4-a-ibenzorciri.2.51oxadiazol-4-ylsulfonvn-iH-indazol-3-vnbenzoic acid SI MS = m/z 421 [M+H]+
Figure imgf000073_0002
15E: 4-d-i2-cvano-5-methylphenylsulfonvn-iH-indazol-3-vnbenzoic acid ESI MS = m/z 418 [M+H]+
Figure imgf000073_0003
Example 16
Figure imgf000074_0001
4-(l-(2-chlorophenylsulfonyl)-lH-pyrazolo[4,3-clpyridin-3-yl)benzoic acid
i) To a solution of 3-bromo-lH-pyrazolo[4,3-c]pyridine (198 mg, 1,0 mmol) in 10 ml THF was added portion wise at 0 °C sodium hydride (101 mg, 4 mmol, 95%). After addition was complete, 2-chlorobenzenesulfonyl chloride (495 mg, 2.347 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched by the addition of water. The product was extracted into ethyl acetate and the organic layer was washed with brine. The organic solvent was evaporated under reduced pressure to give 3-bromo- 1 -(2-chlorophenylsulfonyl)- lH-pyrazolor4,3-c1pyridine as a yellow oil. The product was used in the next step without further purification.
ii) To a microwave reaction vial were added the product obtained in the previous step (67 mg, 0.135 mmol) in 3 ml DME, tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzoate (49.2 mg, 0.162 mmol) and 0.472 ml of a 2M aqueous solution of sodium carbonate (0.944 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (31.2 mg, 0.027 mmol) was added and the reaction mixture was stirred for 40 minutes at
100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with water and washed with ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate.
After filtration the solvent was evaporated under reduced pressure and the product was purified preparative HPLC using 20% to 100% CH3CN in water as the eluent to give tert- butyl 4-(l-(2-chlorophenylsulfonyl)-iH-pyrazolo[4,3-clpyridin-3-yl)benzoate as a yellow solid (16 mg).
iii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(l-(2-chlorophenylsulfonyl)-lH-pyrazolo[4,3-clpyridin-3-yl)benzoic acid, was prepared (7 mg) ESI MS = m/z not measured [M+H]+ Example 17
Figure imgf000075_0001
4-(l-(3,5-dimethylphenylsulfonyl)-lH-indazol-3-yl)-3-fluorobenzoic acid i) 3-bromo-iH-indazole (3 gram; 15 mmol) was dissolved in 30 ml DMF, followed by the addition of sodiumhydride (850 mg, 21 mmol). After stirring for 20 min at room temperature, 3,5-dimethylbenzene-l-sulfonyl chloride (4.4 gram, 21 mmol) was added and the reaction mixture was stirred for another 2 h at room temperature. The reaction was quenched by the addition of water and the formed solids were filtered off and washed with little methanol. The solids were dried to obtain 3-bromo-l-(3,5-dimethylphenylsulfonyl)-lH-indazole (2.1 gram) as a white solid.
ii) The product obtained in the previous step (100 mg, 0.27 mmol), Pd(PPh3)4 (63 mg, 0.05 mmol) and 4-borono-3-fluorobenzoic acid (101 mg, 0.55 mmol ) were stirred in 6.5 ml DME and 3.5 ml of an aqueous solution of NaHC03 (69 mg, 0.82 mmol) was added. The reaction mixture was heated in a microwave reactor for 30 min at 100 C. After cooling, the reaction mixture was filtered over cotton and the volatiles were evaporated under reduced pressure. The crude material was purified by prep. HPLC (Gemini NX column (100 * 30 mm, 5μιη); 40 ml/min; Eluens A: 20 mmol/L NH4HC03 (aq) and Eluens B: acetonitrile; Gradient: 0-7 min 70%A and 30% B; 7-7.1 min 50%A and 50% B; 7.1-8.5 min 100% B) to give the title compound 4-(l-(3,5-dimethylphenylsulfonyl)-lH-indazol-3-yl)-3-fluorobenzoic acid (25 mg) as an off white solid.
ESI MS m/z 425 [M+H]+ Example 18
Following a procedure analogous to that described in Example 17, the following compounds was prepared.
4-(l-(3,5-dimethylphenylsulfonyl)-iH-indazol-3-yl)-2-(trifluoromethyl)benzoic acid
ESI MS m/z 475 [M+H]+
Figure imgf000076_0001
Example 19
5-^4-(4,4,5,5-Tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)-HJ-tetrazole
Figure imgf000076_0002
i) 4-(4,4,5,5-Tetramethyl-l ,3,2-dioxaborolan-2-yl)benzonitrile (8.0 g, 34.8 mmol), trimethylsilyl azide, (8.04 g, 69.8 mmol) and dibutyl-stannanone (868 mg, 3.5 mmol, 0.1 equiv) were dissolved in 1 ,2-dimethoxy ethane (1 10 ml). The mixture was divided in two portions and transferred in two microwave vessels then irradiated in a microwave reactor simultaneously at 150 °C for 10 min. After cooling to room temperature, trimethylsilyl azide (4.02 g, 35 mmol) and dibutyl-stannanone (434 mg, 1.75 mmol) were added into each microwave vessel and the mixtures were irradiated again at 150 °C for 10 min. After cooling to room temperature, the mixtures were combined and purified by column chromatography on florisil (200 g). It was first eluted with 20% dichloromethane in hexane to remove the impurities, then with 10% methanol in dichloromethane to elute the product. l-(4- Methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)-iH-tetrazole 2 was isolated as a white powder (8.01 g).
APCI MS m/z 273 [M + H]+.
ii) The product obtained in the previous step (8.40 g, 30.9 mmol) was dissolved in acetonitrile (150 ml). First potassium carbonate powder (5.12 g, 37.0 mmol, 1.2 equiv), then 4- methoxybenyl chloride (6.3 mL, 46.3 mmol) were added. After stirring at 40 °C for 12 hours the reaction mixture was diluted with ethyl-acetate (100 ml), washed with water (2 x 100 ml) and dried over magnesium sulfate. After filtration the solvent was evaporated under reduced pressure. The residue was suspended in hexane and the formed crystals were filtered. Title compound l-(4-Methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)- 7H-tetrazole was obtained as a white powder as a mixture of regio-isomers (9.67 g).
APCI MS m/z 393 [M + H]+.
Example 20
3- 4-(7H-tetrazol-5-yl)phenyl)-l-(3-chlorophenylsulfonyl)-iH-indazole
Figure imgf000077_0001
i) 7¾rt-butyl 3-bromo-iH-indazole-l-carboxylate (5.0 g, 16.8 mmol) and a mixture of the regio-isomers of l-(4-methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)-7H-tetrazole (Example 19, step ii) (7.92 g, 20.2 mmol) were dissolved in 100 ml of a 1 to 1 mixture of 1,4-dioxane and water under a nitrogen atmosphere. Sodium carbonate (5.35 g, 50.5 mmol) was added and the system was purged with nitrogen.. Then Pd(PPh3)4 (486 mg, 0.42 mmol) was added and the reaction mixture was heated overnight at reflux temperature under a nitrogen atmosphere. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over magnesium sulfate. After filtration the solvent was removed under reduced pressure. The residue was purified on Si02 using 20 to 30% ethyl acetate in hexane as the eluent to give 3-(4-(l-(4-methoxybenzyl)-7H-tetrazol-5-yl)phenyl)-iH- indazole as a mixture of two regioisomers in a 2 to 1 ratio (2.8 g) as a white solid.
Major regio-isomer (1.91 g, 30%) as a white powder.
APCI MS m/z 383 [M + H]+,
ii) To a solution of the product obtained in the previous step (100 mg, 0.26 mmol) in 2ml anhydrous THF was added t-BuOK (32 mg, 0.29 mmol).After stirring the reaction mixture at room temperature for 20 min, 3-Chlorobenzene-l-sulfonyl chloride (41 mg, 0.29 mmol) was added and the mixture was stirred at room temperature for an additional 2 h. After completion, the solvent was evaporated under reduced pressure, the residue was dissolved in
dichloromethane and washed with water. The organic phase was evaporated and the residue was dried under reduced pressure to afford 1 -(3 -chlorophenylsulfonyl)-3 -(4-( 1 -(4- methoxybenzyl H-tetrazol-5-yl)phenyl H-indazole (146 mg, crude) as a brown oil which was used in the next step without any further purification.
ESI MS m/z 557 [M + H]+
iii) The product obtained in the previous step (81 mg) was dissolved in 1 ml trifluoroacetic acid and stirred for 2 days at room temperature. The solvent was evaporated under reduced pressure and the residue was purified by preparative HPLC using eluent sytem 1 then eluent system 2 to afford 3-(4-(7H-tetrazol-5-yl)phenyl)-l-(3-chlorophenylsulfonyl)-iH-indazole (26 mg) as a white powder:
ESI MS m/z 437 [M + H]+
Example 21
Following a procedure analogous to that described in Example 20, the following compounds were prepared.
21A: methyl 3-(3-(4-(7H-tetrazol-5-yl)phenyl)-iH-indazol-l-ylsulfonyl)thiophene-2- carboxylate
ESI MS = m/z 467 [M+H]+
Figure imgf000079_0001
21B: 3-(4-(7H-tetrazol-5-yl)plienyl)-l-(2-bromo-4-fluoroplienylsulfonyl)-iH-indazole
Figure imgf000079_0002
ESI MS = m/z 499/501 [M+H]+
21 -(4-(7H etrazol-5-yl)phenyl)-l-(3-bromo-5-chlorotliioplien-2-ylsulfonyl)-iH-indazole
Figure imgf000079_0003
ESI MS = m z 523 [M+H]+
21D: 4-(3-(4-(7H-tetrazol-5-yl)phenyl)-iH-indazol-l-ylsulfonyl)-3,5-dimetliylisoxazole
Figure imgf000080_0001
ESI MS = m/z 422 [M+H]+
Example 22
-(4-(7H-tetrazol-5-yl)plienyl)-iH-indazol-l-yl)(2,6-dicliloroplienyl)metlianone
Figure imgf000080_0002
i) To a solution of a mixture of regio-isomers of 3-(4-(l-(4-Methoxybenzyl)-7H-tetrazol-5- yPphenyl H-indazole (Example 20, step i) (50 mg, 0.13 mmol) was dissolved in anhydrous THF (1 ml). After addition of t-BuOK (16 mg, 0.14 mmol,) the reaction mixture was stirred at room temperature for 15 min. Subsequently, 2,6-dichlorobenzoyl chloride (21 μΐ, 0.14 mmol) was added and the reaction mixture was stirred for another 2h at room temperature. The solvent was evaporated under reduced pressure, the residue was dissolved in
dichloromethane and washed with water, an aqueous solution of 5% K2CO3 and water. The organic solvent was evaporated under reduced pressure and the residue was dried in vacuo. The product was purified by preparative HPLC to afford (2,6-dichlorophenyl)(3-(4-(l-(4- methoxybenzyl)-7H-tetrazol-5-yl)phenyl)-iH-indazol-l-yl)methanone as a mixture of 2 regioisomers in a 98 to 2 ratio (59 mg, 74%).
ESI MS m/z 555 [M + H] +.
ii) Following a procedure analogous to that described in Example 20, step iii, the product obtained in the previous step was converted to the title compound (3-(4-(7H-tetrazol-5- vDphenyl H-indazol- 1 -yl)(2,6-dichlorophenyl)methanone (16 mg). ESI MS m/z 435 [M + H] +.
Example 23
Following a procedure analogous to that described in Example 22, the following compound was prepared.
Org 356723-0
Figure imgf000081_0001
(3-(4-(iH-tetrazol-5-yl)phenyl)-7H-indazol-l-yl)(2,3-dichlorophenyl)methanone
ESI MS = m/z [M+H]+
Example 24A: Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl) benzoyl)-4- fluoro-/H-indazol-3-yl)-3-fluorobenzoate (24A)
Figure imgf000082_0001
A-5 A-6 24A i) Preparation of 4-fluoro-3-iodo-/H-indazole (A-2). To a solution of 4-fluoroindazole A-l (5.00 g, 36.7 mmol) in DMF (80 mL) was added h (18.6 g, 73.5 mmol) and KOH (7.73 g, 134 mmol) successively at rt. After 2 h, the reaction mixture was poured into aq. 10% NaHS03 (200 mL) and extracted with EtOAc (200 mL*3). The combined organic layers were washed with H20 and brine, dried over Na2S04, and concentrated. The crude solid was washed with PE to give the title compound as a yellow solid. LCMS (ESI) calc'd for C7H5FIN2 [M+H]+: 262.9, found: 262.9. ii) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-iodo-/H- indazol-1- yl)methanone (A-4). To a flask was added compound A-2 (5.24 g, 20 mmol), compound A-3 (4.86 g, 20 mmol), DMAP (2.44 g, 20 mmol) and DCM (30 mL), followed by the addition of TEA (5.8 mL, 40 mmol) slowly. The reaction mixture was stirred at rt for 24 h. The mixture was diluted with H20, and the organic layer was separated. The aqueous layer was extracted with CH2C12. The combined organics were washed with H20, brine, dried over Na2S04, and concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for Ci5H7ClF4IN20 [M+H]+: 468.9, found: 468.9. iii) Preparation of methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-/H- indazol-3-yl)-3-fluorobenzoate (A-5). To a mixture of A-4 (300 mg, 0.64 mmol), 2-fluoro-4- (methoxycarbonyl)phenylboronic acid (190 mg, 0.96 mmol), Pd(dppf)Cl2 (52 mg, 0.064 mmol) and KOAc (190 mg, 1.92 mmol) was added dioxane (10 ml) and H20 (2 ml), and the mixture was heated at 90 ° C under microwave for 2 h. The mixture was cooled down, diluted with CH2C12 (50 ml). The organic layer was separated, washed with brine, dried over Na2S04, concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to give the title compound. LCMS (ESI) calc'd for C23H13CIF5N2O3 [M+H]+, 495, found: 495. iv) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-/H- indazol-3-yl)- 3-fluorobenzoic acid (A-6). To a solution of A-5 (180 mg, 0.36 mmol) in THF (5mL) and H20 (5mL) was added LiOH (350 mg, 1.44 mmol), and the mixture was stirred at rt for 24 h. The mixture was neutralized with 2N HC1 to PH = 3~4. The mixture was then concentrated under reduced pressure. The residue was filtered and washed with H20 to afford the title compound as white solid. LCMS (ESI): calc'd for C22H11CIF5N2O3 [M+H]+: 481, found: 481; 1H NMR (400 MHz, CDC13) δ 8.45-8.47 (1H, d), 7.88-7.95 (2H, m), 7.66-7.71 (3H, m), 7.58- 7.64 (2H, m), 7.13-7.17 (1H, m). v) Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-/H- indazol-3-yl)-3-fluorobenzoate (24A). To a suspension of compound A-6 (160 mg, 0.33 mmol) in H2O (10 mL) was added 0.1M NaOH (3.3 ml, 0.33 mmol) and the mixture was kept stirring at 0 °C for 30 mins. The reaction mixture was dried under lyophilization to afford the title compound. LCMS (ESI) calc'd for C22H11CIF5N2O3 [M-Na+2H]+: 481, found: 481; 1HNMR (400 MHz, DMSO) δ 8.36-8.38 (1H, d), 7.96-8.03 (2H, m), 7.66-7.71 (1H, m), 7.85- 7.89 (1H, m), 7.72-7.74 (1H, m), 7.65(1H, s), 7.40-7.45(2H, m). Example 24B: Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl) indazol-3- yl)benzoate (24B)
Figure imgf000084_0001
B-4 24E i) Preparation of (3-bromo-/H-indazol-l-yl)(2-chloro-6-(trifluoromethyl) phenyl)methanone (B-2). To a solution of 3-bromo-iH-indazole (2 g, 0.75mmol), DMAP (1 g, 8.5 mmol) and Et3N (1.85 ml, 12.7 mmol) in CH2CI2 (20 mL) at 0 °C was added a solution of compound A-3 (4 g, 20.4 mmol) in CH2CI2 (5 mL). The mixture was stirred at rt for 24 h, diluted with CH2CI2, washed with 1M HC1. The organic layer was washed with sat. NaHC03 and brine, dried over anhydrous Na2S04 and concentrated. The residue was purified by flash chromatography (PE/EA=10/1) to give the title compound. LCMS (ESI) calc'd for Ci5H8BrClF3N20 [M+H]: 404.9, Found: 404.9. ii) Preparation of methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- indazol-3- yl)benzoate (B-3). A mixture of compound B-2 (3.0 g, 7.4 mmol), 4- (methoxycarbonyl)phenylboronic acid (1.6 g, 8.9 mmol), Pd(PPh3)4 (0.43g, 0.37 mmol) and K2C03 (2.04 g, 10.8 mmol) in dioxane (10 mL) and H20 (2 mL) was heated at 140 °C for 2 h under microwave. The mixture was cooled down, diluted with CH2CI2 and H20. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by flash chromatography (PE/EA = 10/1) to give the title compound as a yellow solid. LCMS (ESI) calc'd for C23H15CIF3N2O3 [M+H]+: 459, found: 459. iii) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H-indazol-3- yl)benzoic acid (B-4). A mixture of compound B-3 (1.3 g, 2.8 mmol) and LiOH (0.35 g, 8.4 mmol) in THF (5 mL) and ¾0 (5 mL) was stirred at rt for 24 h. Then the mixture was neutralized with AcOH to PH < 7, diluted with CH2CI2 and H20. The organic layer was separated and washed with brine, dried over Na2S04 and concentrated. The residue was purified by prep HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C22H13CIF3N2O3 [M+H]+: 445, found: 445; 1H NMR (400 MHz, CDC13) δ 8.68-8.71 (1H, d), 8.19-8.21 (2H, m), 8.03- 8.05 (1H, d), 7.94-7.96 (2H, m), 7.70-7.75 (3H, m), 7.26-7.63 (2H, m). iv) Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- indazol-3- yl)benzoate (24B). To a suspension of compound B-4 (0.87g, 2.0 mmol) in ¾0 (10 mL) at 0
°C was added 0.1 M NaOH (2.0 ml, 2.0 mmol) and the mixture was kept stirring at at 0 °C for 30 mins. The mixture was dried under lyophilization to give the title compound. 1H NMR (400 MHz, DMSO) δ 8.54-8.56 (1H, d), 8.22-8.24 (1H, d), 8.03-8.05 (1H, d), 7.98-8.00 (3H, m), 7.82-7.88 (2H, m), 7.71-7.73 (2H, m), 7.63-7.67 (1H, t).
Example 24C: Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl) -1H- pyrazolo [4,3-b]pyridin-3-yl)-3-fluorobenzoate (24C)
Figure imgf000086_0001
i) Preparation of (3-bromo-/H-pyrazolo[4,3-b]pyridin-l-yl)(2-chloro-6- (trifluoromethyl)phenyl)methanone (C-2). To a mixture of compound A-3 (1.2 g, 5.0 mmol), compound C-1 (1.0 g, 5.0 mmol), and DMAP (0.61 g, 5.0 mmol) in CH2C12 (20 mL) was added TEA (0.55 g, 5.5 mmol) dropwise. The mixture was stirred at rt for 24 h., diluted with H20, and the organic layer was separated. The aqueous layer was extracted with CH2C12. The combined organics were washed with H20, brine, dried over Na2S04, and concentrated. The residue was purified by column chromatography (PE/EA from 50/1 to 10/1) to give the title solid. LCMS (ESI) calc'd for Ci4H7BrClF3N30 [M+H]+: 405.9, found: 405.9. ii) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H-pyrazolo[4,3-b] pyridin-3-yl)-3-fluorobenzoic acid (C-3). A mixture of C-2 (120 mg, 0.3 mmol), 2-fluoro-4- (methoxycarbonyl)phenylboronic acid (89 mg, 0.45 mmol), Pd(PPh3)4 (18 mg, 0.015 mmol) and K2C03 (128 mg, 0.75 mmol) in dioxane (3 mL) and H20 (0.6 mL) was heated at 140°C for 3 h under microwave. The mixture was cooled down and diluted with CH2C12 and H20. The organic layer was washed with brine, dried over Na S04 and concentrated. The residue was purified by flash chromatography (PE/EA=1/1) to give the title compound as a yellow solid. LCMS (ESI) calc'd for C22Hi3ClF4N303 [M+H]+: 464, found: 464; 1H NMR (400 MHz, DMSO) δ 13.51 (1H, s), 8.98-8.91 (2H, m), 8.42-8.38 (2H, t), 8.06-7.95 (3H, m), 7.90-7.87 (2H, m), 7.87-7.80 (1H, m). iii) Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- pyrazolo[4,3- b]pyridin-3-yl)-3-fluorobenzoate (24C). To a suspension of compound C-3 (135 mg, 0.29 mmol) in H20 (20 mL) was added 0.1 M NaOH (2.9 ml, 0.29 mmol) at 0 °C, and the mixture was kept stirring for 30 min at 0 °C. The mixture was then dried under lyophilization to give the title compound. LCMS (ESI) calc'd for C21H11CIF4N3O3 [M-Na+2H]+: 464, found: 464, 1H NMR (400 MHz, CD3OD) δ 8.95-8.93 (1H, m), 8.89-8.87 (1H, m), 8.13-8.09 (1H, t), 7.90-7.87 (3H, m), 7.81-7.75 (3H, m).
The following examples shown in TABLE 2 were prepared following similar procedures described for Examples #24 A, B, C in Schemes A-C, which can be achieved by those of ordinary skill in the art.
TABLE 2
Figure imgf000087_0001
Figure imgf000087_0002
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
acid
Figure imgf000092_0001
lH-indazol-3-
Figure imgf000093_0001
yl)methanone
Figure imgf000094_0001
Figure imgf000095_0001
yl)benzoic acid
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
yl)benzoic acid Example 25A: Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl) -6-(2- hydroxy ethylcarbamoyl)-/H-indazol-3-yl)benzoate (25A)
Scheme D.
Figure imgf000100_0001
D-7 D-8 25A i) Preparation of methyl /H-indazole-6-carboxylate (D-2).
To a solution of methyl 3-amino-4-methylbenzoate D-l (5.0 g, 30 mmol) in AcOH (140 mL) at 0 °C was added a solution of sodium nitrite (2.1 g, 30 mmol) in H20 (3.5 mL). After addition, the mixture was stirred at rt for 24 h. Then half of the solvent was removed under reduced pressure and the resulting mixture was diluted with H20, and extracted with EtOAc. The combined orgnaics were washed H20 and brine, and concentrated to give the title compound. LCMS (ESI) calc'd for C9H9N2O2 [M+H]+: 177, found 177. ii) Preparation of methyl 3-iodo-/H-indazole-6-carboxylate (D-3). To a solution of methyl 7H-indazole-6-carboxylate D-2 (5.0 g, 28 mmol) in DMAC (50 mL) at 0 °C was added iodine (14.4 g, 56.7 mmol) and potassium hydroxide (6.3 g, 114 mmol) portionwise. After addition, the mixture was kept stirring for 1 h, then quenched with aq. Na2S203 and extracted with EtOAc. The combined organics were concentrated and trituated with hexane. The precipitate was collected by filtration to afford the title compound as a brown solid. LCMS (ESI) calc'd for C9H8IN202 [M+H]+: 302.9, found: 302.9. iii) : Preparation of methyl l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-iodo- /H-indazole- 6-carboxylate (D-4).
To a solution of methyl 3-iodo-iH-indazole-6-carboxylate D-3 (11.7 g, 38.7 mmol), DMAP (4.72 g, 38.7 mmol) in CH2CI2 (30 mL) was added Et3N (11.2 mL, 77 mmol) dropwise. The reaction mixture was stirred at rt for 24 h, diluted with ¾0, and the organic layer was separated. The aqueous layer was extracted with CH2CI2 twice. The combined organics were washed with H20, brine, dried over Na2S04, concentrated. The residue was purified by column chromatography (PE /EtOAc from 50/1 to 10/1) to give the title compound. LCMS (ESI) calc'd for CI7HIOC1F3IN203 [M+H]+: 508.9, found: 508.9. iv) : Preparation of l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-iodo-/H- indazole -6- carboxylic acid (D-5).
To a solution of D-4 (16.5 g, 32.5 mmol) in THF (10 mL) and H20 (50 ml) was added LiOH (3.40 g, 162 mmol), and the mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure and the residue was taken up in H20, and neutralized with 5% aqueous HCl to PH = 4~5. The white precipitate was collected by filtration, washed with ¾0 and hexane to give the title compound as an off- white solid. LCMS (ESI) calc. Ci6H8ClF3rN203 [M+H]+: 494.9, found: 494.9. v) Preparation of l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-/H-indazole-6-carboxylic acid (D-6).
A mixture of D-5 (300 mg, 0.61 mmol), 4-(methoxycarbonyl)phenylboronic acid (165 mg, 0.92 mmol), Pd(dppf)Cl2 (50 mg, 0.061 mmol) and KOAc (181 mg, 1.83mmol) in dioxane (10 mL) and H20 (2 mL) was heated at 95 °C for 2 h under microwave. The mixture was then cooled to rt, diluted with EtOAc and H20. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by flash chromatography (PE/EtOAc =20/1) to give the title compound as a white solid. LCMS (ESI) calc'd for C24H15CIF3N2O5 [M+H]+: 503.1 , found: 503.1. vi) Preparation of methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2- hydroxyethylcarbamoyl)-/H-indazol-3-yl)benzoate (D-7).
To a solution of compound D-6 (180 mg, 0.36mmol) in CH2C12 (15 mL) was added PYAOP (374 mg, 0.72mmol), followed by the addition of Et3N (0.16mL, 1.1 mmol). The mixture was stirred at rt for 2 h, diluted with EtOAc. The organic layer was separated, washed with brine, dried over Na2S04, concentrated to give the title compound as a white solid. LCMS (ESI) calc'd for C26H2oClF3N305 [M+H]+: 546.1 , Found: 546.1. vii) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)-/H-indazol-3-yl)benzoic acid (D-8).
A mixture of D-7 (191mg, 0.35 mmol) and LiOH (42mg, 1.75 mmol) in THF (10 mL) and H20 (5 mL) was stirred at rt for 2 h. The solvent was removed under reduced pressure, and the residue was dissolved in H20 and neutralized with aqueous 5% HC1 to PH = 4-5. The precipitated was collected by filtration, washed with H20 and hexane to the title compound as an off-white solid. LCMS (ESI) calc'd for C25Hi8ClF3N305 [M+H]+: 532.1 , found: 532.1 ; 1H NMR (400 MHz, MeOD) δ 9.109 (1H, s), 8.29-8.31(lH, d, J = 8.4 Hz), 8.17-8.19 (2H, d, J = 8.4 Hz), 8.07-8.10 (1H, m), 7.97-8.00 (2H, d, J = 8.8 Hz), 7.88-7.99 (2H, m), 7.78-7.82 (1H, m), 3.79-3.82 (2H, m), 3.60-3.63 (2H, m). viii) Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6- (2- hydroxyethylcarbamoyl)-lH-indazol-3-yl)benzoate (25A)
To a suspension of compound D-8 (185 mg, 0.35 mmol) in H20 (10 mL) was added 0.1M NaOH (3.5 ml, 0.35 mmol) at 0 °C, and the mixture was kept stirring for 30 mins. The mixture was then dried under lyophilizaiton to give the title compound. LCMS (ESI) calc. C25Hi8ClF3N305 [M-Na+2H]+: 532, found: 532; 1H NMR (400 MHz, MeOD) δ 9.09 (1H, s), 8.28-8.30 (1H, d, J = 8.8 Hz), 8.05-8.09 (3H, m), 7.86-7.91 (4H, m), 7.77-7.86 (1H, m), 3.79- 3.82 (2H, m), 3.60-3.63 (2H, m). The following examples shown in TABLE 3 were prepared following similar procedures described for Example #25A in Scheme D, which can be achieved by those of ordinary skill in the art. TABLE 3
Figure imgf000103_0001
Figure imgf000103_0002
Figure imgf000104_0001
Figure imgf000105_0001
acid
Figure imgf000106_0001
OH
)benzoyl)-6-
Figure imgf000107_0001
P
Figure imgf000108_0001
Figure imgf000109_0001
yl)benzoic acid Example 26: Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1H- indazol-3-yl)-2-hydroxybenzoic acid (26A), 2-acetoxy-4-(l-(2-chloro-6-(tri fluoromethyl) benzoyl)-4-fluoro-/H-indazol-3-yl) benzoic acid (26B) and sodium 4-(l-(2-chloro-6- (trifluoromethyl)benzoyl)-4-fluoro-/H-indazol-3-yl)-2-hydroxy benzoate (26C)
Scheme E.
Figure imgf000110_0001
i) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-/H- indazol-3-yl)- 2-hydroxybenzoic acid (26A)
To a solution of compound E-1 (prepared following a similar procedure in Scheme A) (100 mg, 0.19 mmol) in DCM (10 mL) was added BBr3 (1M, 0.37 mL, 0.37 mmol) at rt, and the mixture was kept stirring for 48 h. Then MeOH (~10 mL) was added to quench excess BBr3 and the mixture was concentrated under reduced pressure. The residue was purified by prep- HPLC to give the title compound as a yellow solid. LCMS (ESI) calc'd for C22H12CIF4N2O4 [M+H]+: 479, found: 479; JH NMR (400 MHz, MeOD) δ 8.46 (1H, d, J=8.4 Hz), 7.95-7.76 (5H, m), 7.35-7.29 (3H, m). ii) Preparation of 2-acetoxy-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-/H- indazol-3-yl)benzoic acid (26B)
A suspension of compound 26A (48 mg, 0.1 mmol), Ac20 (0.8 mL) and Mgl2 (28 mg, 0.1 mmol) in anhydrous ethyl ether (3 mL) was refluxed at 40 °C for 0.5 h. The reaction was cooled to rt, quenched with H20, extracted with ether, and concentrated. The crude product was dissolved in THF (10 mL) /H20 (10 mL) and refluxed at 80 °C for 1 h. The mixture was cooled to rt, diluted with H20, and extracted with EtOAc. The combined organic extracts were concentrated and purified by flash chromatography PE/EA (5/1) to give the title compound as a white solid. LCMS (ESI): calc'd for C22H12CIF4N2O4 [M+H]+: 521, found: 521, 1H NMR (400 MHz, MeOD) δ 8.47 (1H, d, J=8.0 Hz), 8.11 (1H, d, J=8.0 Hz), 7.90-7.76 (5H, m), 7.53 (1H, t, J=1.6 Hz), 3.34 (1H, q, J=8.0 Hz), 2.31 (3H, s). iii) Preparation of sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)- 4-fluoro-/H- indazol-3-yl)-2-hydroxybenzoate (26C)
To a suspension of compound 26A (48 mg, 0.1 mmol) in H20 (20 mL) was added 0.1 M NaOH (1 mL), and the mixture was sonicated for ~10 mins. The mixture was then dried under lyophihzaiton to give the title compound. LCMS (ESI) calc'd for C22HiiClF4N2Na04 [M+H]+: 501, found: 501; JH NMR (400 MHz, MeOD) δ 8.45 (1H, d, J=8.0), 7.91-7.76 (5H, m), 7.31 (1H, q, J=8.0 Hz), 7.20-7.17 (2H, m).
The following examples shown in TABLE 4 were prepared following similar procedures described for Examples #26A, B, C in Scheme E, which can be achieved by those of ordinary skill in the art.
TABLE 4
Figure imgf000112_0001
acid
Figure imgf000113_0001
Figure imgf000114_0001
acid
Example 27A: Preparation of 4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl) benzoyl)-/H- indazol-3-yl)benzoic acid (27A)
Scheme F.
Figure imgf000115_0001
i) Preparation of methyl 4-(6-carbamoyl-l-(2-chloro-6-(trifluoromethyl) benzoyl)-/H- indazol-3-yl)benzoate (F-2)
To a solution of compound D-6 (180 mg, 0.36 mmol) in DCM (15 mL) was added PYAOP (374 mg, 0.72mmol), followed by the addition of TEA (0.16 mL, 1.1 mmol). The mixture was stirred at rt for 2 h, diluted with EtOAc, washed with brine, dried over Na2S04 and concentrated to give the title compound. LCMS (ESI) calc'd for C24Hi6ClF3N304 [M+H]+: 502, found: 502.1. ii) Preparation of (6-(aminomethyl)-3-(4-(hydroxymethyl)phenyl)-/H-indazol- l-yl)(2- chloro-6-(trifluoromethyl)phenyl)methanone (F-3)
To a solution of compound F-2 (175 mg, 0.35 mmol) in THF (20 mL) was added BH3 THF (1.75 mL, 1.75 mmol) and the mixture was re fluxed for 12 h. Then MeOH was added to quench the excess BH3j and the mixture was concentrated under reduced pressure to give the title compound as a white solid. LCMS (ESI): calc'd for C23Hi8ClF3N302 [M+H]+: 460.1 , found: 460.1. iii) Preparation of tert-butyl (l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4- (hydroxymethyl)phenyl)-/H-indazol-6-yl)methylcarbamate (F-4) To a solution of compound F-3 (138 mg, 0.30 mmol) in CH2CI2 (20 mL) was added (Boc)20 (138 mg, 0.30 mmol), followed by the addition of excess. The mixture was stirred at rt for 2 h. The mixture was diluted with H20, extracted with EtOAc. The combined organics were washed with H20, brine, dried over Na2S04, concentrated to give the title compound. LCMS (ESI) calc. C28H26C1F3N304 [M+H]+: 560.1, found: 560.1. iv) Preparation of 4-(6-((tert-butoxycarbonylamino)methyl)-l-(2-chloro-6-(trifl uoromethyl)benzoyl)-/H-indazol-3-yl)benzoic acid (F-5)
To a solution of compound F-4 (162 mg, 0.29 mmol) in acetone (10 mL) was added Jones reagent (2 mL), and the mixture was kept stirring at rt for 12 h. MeOH (20 mL) was added to quenched excess Jones reagent, and the mixture was filtered and rinsed with EtOAc. The organic layer was separated and concentrated to give the title compound. LCMS (ESI): calc'd for C28H24C1F3N305 [M+H]+: 574.1, Found: 574.1. v) Preparation of 4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl) benzoyl) -1H- indazol-3-yl)benzoic acid (27A)
To a solution of compound F-5 (100 mg, 0.17 mmol) in CH2CI2 (10 mL) was added excess amount of TFA. The mixture was stirred at rt for 2 h. The mixture was concentrated, diluted with H20, and extracted with EtOAc. The combined organics were washed with H20, brine, dried over Na2S04 and concentrated to give the title compound. LCMS (ESI): calc'd for C23Hi6ClF3N303 [M+H]+: 474.1, found: 474.1; 1H NMR (400 MHz, MeOD) δ 8.76 (1H, s), 8.23-8.25 (1H, m), 8.04-8.06 (2H, d, J = 6.8Hz), 7.88-7.91 (2H, m), 7.77-7.85 (3H, m), 7.66- 7.68 (1H, d, J = 8.8 Hz), 4.35 (2H, s).
The following examples shown in TABLE 5 were prepared following similar procedures described for Example #27A in Scheme F, which can be achieved by those of ordinary skill in the art.
TABLE 5
Figure imgf000117_0001
acid
Example 28: Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H-in dazol-3- -2-(difluoromethyl)benzoic acid
Figure imgf000118_0001
G-5 28 i) Preparation of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzo furan-l(3H - one (G-l)
A mixture of 5-bromoisobenzofuran-l(3H)-one (1.5 g, 7.0 mmol), 4,4,4',4', 5,5,5',5'- octamethyl-2,2'-bi(l,3,2-dioxaborolane) (2.1 g, 8.5 mmol), KOAc (2.1 g, 21 mmol), dppf (0.16 g, 0.28 mmol) and Pd(dppf)Cl2 (0.26 g, 0.35 mmol) in dioxane (30ml) was heated at 100 °C for 4 h. The mixture was cooled down and concentrated under reduced pressure. The residue was diluted with H20, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2S04, and concentrated. The residue was purified by flash chromatography (PE: EA = 5: 1) to give the title compound as a white solid. LCMS (ESI)xalc. Ci4Hi8B04 [M+H]+: 261, found: 261. ii) 5-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H-indazol-3-yl)isobenzo furan-1 (3H)- one (G-2)
A mixture of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran-l(3H)- one (G-1) (0.97 g, 2.48 mmol), (3-bromo-lH-indazol-l-yl)(2-chloro-6-(trifluoro
methyl)phenyl)methanone (1.0 g, 2.48 mmol), K2C03 (1.03 g, 7.44 mmol) and Pd(PPh3)4 (0.143 g, 0.12 mmol) were suspended in 1,4-dioxane (15 mL) and H20 (3 mL). The reaction mixture was heated at 100 °C in a microwave reactor for 2 h. The reaction mixture was cooled to rt and diluted with H20. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2S04 and concentrated. The residue was purified by flash chromatography (PE: EA = 4:1) to afford the title compound as a pale yellow oil. LCMS (ESI) calc'd for C23Hi3ClF3N203 [M+H]+: 457, found: 457. iii) Preparation of benzyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- indazol-3-yl)-2- (hydroxymethyl)benzoate (G-3)
A mixture of 5-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-iH-indazol-3-yl)isobenzo furan- l(3H)-one (G-2) (0.6 g, 1.32 mmol) and LiOH (0.16 g, 6.58 mmol) in THF (6 mL) and H20 (3mL) was stirred at rt for 3 h. The solvent was removed under reduced pressure, and the residue was dissolved in DMF (10 mL), followed by the addition of BnBr (0.78 mL, 6.6 mmol). The resulting mixture was stirred at rt for 3 h. The mixture was diluted with H20, and EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2S04 and concentrated. The residue was purified by flash chromatography (PE: EA = 4: 1) to give the title compound as a colorless oil. LCMS (ESI) calc'd for C30Hi9ClF5N2O3 for [M+H]+: 585, found: 585. iv) Preparation of benzyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- indazol -3-yl)- 2-formylbenzoate (G-4)
To a mixture of benzyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3- yl)-2- (hydroxymethyl)benzoate (G-3) (0.4 g, 0.71 mmol) in DCM (10 mL) was added Dess-Martin periodinane (0.45 g, 1.07 mmol), and the mixture was stirred at rt for 24 h. The mixture was diluted with H20 and extracted with DCM. The combined organic layers were washed with brine, dried over Na2S04 and concentrated. The resulting crude oil was used in the next step without further purification. LCMS (ESI)* calc'd for C3oHi9ClF3N204 [M+H]+: 563, found: 563. v) Preparation of benzyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H- indazol-3-yl)-2- (difluoromethyl)benzoate (G-5)
To a solution of compound (G-4) (0.35 g, 0.62 mmol) in DCM (6 mL) at 0 °C was added a solution of DAST (0.42 mL, 3.1mmol) in DCM (4 mL) dropwise. The mixture was warmed to rt and stirred for 2 h. The reaction mixture was then diluted with H20, and extracted with DCM. The combined organics were washed with brine, dried over Na2S04, and concentrated. The residue was purified by flash chromatography (PE: EA = 10: 1) to give the title compound as a white solid. LCMS (ESI) calc'd for C3oHi9ClF5N203 [M+H]+: 585, found: 585. vi) 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-/H-indazol-3-yl)-2-(difluorometh yl) benzoic acid (28)
A mixture of compound (G-5) (0.17 mg, 0.30 mmol) and LiOH (63 mg, 1.5 mmol) in THF (6 mL) and H20 (3 mL) was stirred at rt for 24 h. The mixture was acidified with 2M HC1 to PH = ~3, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2S04 and concentrated. The residue was purified with prep-HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C23Hi3ClF5N203 [M+H]+: 495, found: 495; 1H NMR (400 MHz, CDC13) δ 8.70 (1H, d, J = 8 Hz), 8.35 (1H, s), 8.25 (1H, d, J = 8Hz), 8.02-8.05 (2H, m), 7.71-7.77 (3H, m), 7.49-7.64 (3H, m).
Example 29: Preparation of 4-(l-(2-chloro-6-(trifluoromethyl) benzoyl)-6-cyano -1H- indazol- 3-yl)benzoic acid Scheme H.
Figure imgf000121_0001
i) Preparation of methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6- cyano-/H- indazol-3-yl)benzoate (H-2)
To a solution of compound H-l (100 mg, 0.186 mmol) (prepared according to a similar procedure in Scheme A) in DMF (2 mL) was added Zn(CN)2 (44 mg, 0.37 mmol) and Pd(PPh3)4 (22 mg, 0.019 mmol). The mixture was purged with N2 and then stirred at 100 °C for 1 h under micorwave. The reaction mixture was cooled down to rt and diluted with H20, and extracted with EtOAc. The combined organics were dried over anhydrous Na2S04, filtered and concentrated. The crude solid was purified by Prep-TLC (20*20cm)(PE/EA=3/l) to obtain the title compound as a brown solid. LCMS (ESI) calc'd for C24Hi4F3N303Cl [M+H]+: 484, Found: 484. ii) Preparation of 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-/H- indazol-3- yl)benzoic acid (29)
A mixture of compound H-2 (49 mg, 0.10 mmol), and LiOH (37 mg, 0.88 mmol) in dioxane (10 mL) and H20 (2 mL) was stirred at rt for 24 h. The mixture was acidified with AcOH to PH = ~4, and extracted with DCM. The combined organics were washed with brine, dried over anhydrous Na2S04 and concentrated. The residue was purified by prep HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C23Hi2F4N303Cl [M+H]+: 470, found: 470; 1H NMR (400 MHz, DMSO) δ 13.23 (1H, s), 8.99 (1H, s), 8.49 (1H, d, J=8.4 Hz), 8.03- 8.12 (5H, m), 7.89-7.98 (3H, m). Biological Assays
The compounds of the invention inhibit RORgammaT activity. Activation of
RORgammaT activity can be measured using e.g. biochemical TR-FRET assay. In such an assay, interaction of cofactor-derived peptides with human RORgammaT-Ligand Binding Domain (LBD) can be measured. The TR-FRET technique is a sensitive biochemical proximity assay that will give information concerning the interaction of a ligand with the LBD, in the presence of cofactor derived peptides (Zhou et al., Methods 25:54-61, 2001).
To identify novel antagonists of RORgammaT, an assay was developed which employs the interaction of RORgammaT with its co-activator peptide SRC 1 2. This peptide mimics the recruitment of co-activators to RORgammaT through its interaction with the LXXLL (eg NR box) motifs (Xie et al., J. Immunol. 175: 3800-09, 2005; Kurebayashi et al., Biochem. Biophys. Res. Commun. 315: 919-27, 2004; Jin et al, Mol. Endocrinology 24:923-29, 2010). The assay was run following three slightly different protocols, i.e. Protocol A, Protocol B, and Protocol C, which are described below. The TR-FRET assay following Protocol A is described below and the results thereof shown in Table 1 below.
TR-FRET assay (Protocol A)
In the current setting, a peptide from Steroid Receptor Co-factor 1 box 2 (SRC 1 2) is aminoterminal biotinylated (biotinyl-CPSSHSSLTERHKILHRLLQEGSPS, NEOMPS, France) and the applied RORgamma-LBD contains a 6-His and GST tag. The
6His(GST)RORgamma-LBD was expressed and purified from baculovirus infected Sf-21 insect cells (Bac-to-BAC, Invitrogen) and purified using glutathione sepharose
chromatography (GE healthcare). Biotin and His function as anchoring points for
streptavidin-allophycocyanin (Strep-APC, Perkin Elmer, CI 30- 100) and anti-His-Europium Cryptate (Perkin Elmer, AD0111), respectively. Since energy transfer between the streptavidin and His-coupled labels APC and europium cryptate can only take place when these labels are in close proximity, measurement of energy transfer in a mixture of biotinylated peptide, His-GR-LBD, streptavidin- APC and anti-His-Europium Cryptate will be indicative for RORy-LBD/peptide binding. Final assay conditions in 50 μΐ are: TR-FRET buffer [50 mM KC1, 50 mM TRIS, 1 mM Na-EDTA, 0.1 mM DTT, (pH 7.0)];
6His(GST)RORgamma-LBD 10 nM, Anti-6His-Eu 1.25 nM, SRC 1 2 peptide 0.1 μΜ, Strep- APC 8 nM. Changes in peptide binding caused by dose-curves of compounds added to the reaction mixture (DMSO concentration 0.1 %), can likewise be monitored. Fluorescence emission at 665 nm (excitation wavelength 340 nm) was read in each well of 384 well plates (Perkin Elmer, 60007299) using an Envision fluorescence reader in Time Resolved mode (Perkin Elmer) after overnight incubation at 4°C. Dose-response data are curve-fitted (IBDS Software, ActivityBase) and pEC50 values calculated. pEC50 values for Examples 1-23 using Protocol A are provided in Table 6 below. All compounds of the invention have a pEC50 of 4 or higher. Preferred are compounds with a pEC50 of more than 5.
Table 6
Figure imgf000123_0001
11F 7.4
11G 7.22
11H 7.15
111 7.14
11J 5.72
UK 7.67
11L 7.58
11M 7.98
UN 7.59
12 7.17
13A 6.81
13B 7.1
13C 7.12
13D 7.28
13E 7.58
13F 6.78
14 5.71
15A 6.56
15B 6.74
15C 7.85
15D 5.35
15E 6.29
17 5.91
18 5.48 16 6.02
20 5.45
21A 6.41
21B 6.24
21C 6.21
21D 6.13
22 5.3
23 5.99
TR-Fret assay (Protocol B)
HIS-tagged RORy-LBD was recombinantly expressed in SF9 cells using a baculovirus expression system. The protein was not purified. Cells were lysed and the lysate was used as a source for RORy-LBD for the assay. A 1 :80 dilution of RORy-LBD lysate in assay buffer (25 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Tween, 0.1% BSA) was prepared and 5 was added to each well (RORy-LBD final concentration ~10 nM). Control wells received lysate from SF9 cells not expressing RORy-LBD.
Compounds to be tested were diluted to lOOx final test concentration in DMSO and further diluted to 4x final test concentration using assay buffer to provide the test compound mixture. An aliquot (5 μί) of the test compound mixture was added to each well.
A 4x stock of biotinylated-LXXLL peptide from SRC 1-2 (Biotin- CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and & 5 μΙ, aliquot added to each well (450 nM final concentration). A 4x solution of europium tagged anti-HIS antibody (2 nM final concentration) and APC conjugated streptavidin (60 nM final concentration) were prepared and & 5 μΐ, aliquot added to each well.
The final assay mixture was incubated for 4 hours to overnight, and the fluorescence signal was measured on an Envision plate reader: (Excitation filter = 340 nm; APC emission = 665 nm; Europium emission = 615 nm; dichroic mirror = D400/D630; delay time = 100 μ8, integration time = 200 μ8). IC50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm using GraphPad Prism software.
TR-Fret assay (Protocol C)
HIS-tagged RORy-LBD protein was expressed in SF9 cells using a baculovirus expression system. The RORy-LBD protein was purified by glutathione sepharose chromatography. Separately, SF9 cells not expressing any recombinant protein were lysed and the lysate was added to the purified RORy-LBD at 0.25 μΐ lysate (from 10,000 SF9 cells)/nM purified protein. The mixture was then diluted in assay buffer (50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT) to obtain RORy-LBD final concentration of 3 nM in 384-well assay plate.
Compounds to be tested were injected to the assay plate using Acoustic Droplet Ejection technology by Echo 550 liquid handler (Labcyte, CA).
A stock of biotinylated-LXXLL peptide from coactivator SRC1 (Biotin- CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and added to each well (100 nM final concentration). A solution of Europium tagged anti-HIS antibody (1.25 nM final concentration) and APC conjugated streptavidin (8 nM final concentration) were also added to each well.
The final assay mixture was incubated for overnight at 4°C, and the fluorescence signal was measured on an Envision plate reader: (Excitation filter = 340 nm; APC emission = 665 nm; Europium emission = 615 nm; dichroic mirror = D400/D630; delay time = 100 μ8, integration time = 200 μ8).Κ^50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm.
Table 7 below tabulates the biological data disclosed for Examples 24A-29 as a range of Fret IC50 values, which was reported as ranges according to the annotation delineated below:
Figure imgf000126_0001
** IC50 >50 and <500 nM
*** IC50 >500 and <10000 nM
**** IC50 >10000 nM Table 7
Figure imgf000127_0001
W B 4X B 4Y B
****
4Z B AA B AB B AC B AD B AE B AF B AG B AH B AI B AJ B AK B
****
AL C AM B AN B AO B AP B AQ B AR B AS C AT B 4AU c4AV c AW c4AX B4AY B4AZ B4BA B4BB B4BC B4BD B4BE B4BF B4BG C 5A B 5B B 5C B 5D B 5E B 5F B 5G B 5H B
251 B
25J B 5K B 25L B
25M B
25N C
250 B
25P B
25Q B
25R B
25S C
25T C
25U C
25V C 5W C
26A B
26B B
26C B
26D B
26E B
26F C
26G C
26H B
261 B
26J B
27A B
27B B 28 B
29 B

Claims

A compound according to Formula I
Figure imgf000132_0001
I or a pharmaceutically acceptable salt or solvate thereof wherein,
X is C(O), SO or S02,
Y is CH or N;
n = 0, 1, 2, 3 or 4;
4 7 4 5 6 7
A -A are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A4- A7 can be simultaneously N;
R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci_ 3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci-3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens; or (iii) (C6- i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci-3)alkoxycarbonyl, (di)(Ci.6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci_4)alkyl or (Ci-3)alkoxy are optionally substituted with one or more halogens;
R2 is C(0)OH, 5-tetrazoylyl, HOC(CF3)2, C(0)OH(Ci.io)alkyl, (Q.
io)alkylsulfoxyaminocarbonyl; or carbamoyl;
R3 is hydrogen, halogen, cyano, nitro, hydroxy, (Cl-3)alkylC(0)0-, (Ci-4)alkyl, or (Ci_ 4)alkoxy, wherein (Ci-4)alkyl and (Ci-4)alkoxy are optionally substituted with one or more halogen;
R4-R7 independently are H, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, (Ci-4)alkyl, (Co-io)alkyl)aminocarbonyl, (di)(Ci.6)alkylaminocarbonyl or amino(Ci-4)alkyl, wherein (Ci-3)alkoxy, (Ci-4)alkyl, (Co-io)alkyl)aminocarbonyl, (di)(Ci-6)alkylaminocarbonyl and amino(Ci-4)alkyl are optionally substituted with one or more halogen, hydroxyl or (Ci_
3)alkoxy; or a group having the
Figure imgf000133_0001
optionally substituted with one or more of the following: (Ci.io)alkyl, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, and wherein m is 1 , 2, 3, or 4.
A compound according to Formula la
Figure imgf000133_0002
la or a pharmaceutically acceptable salt or solvate thereof
wherein X represents C(O), SO or S02,
Y is CH or N;
4 7 4 5 6 7
A -A are independently N or CR , CR , CR or CR , respectively, with the proviso that no more than two of the four positions A4- A7 can be simultaneously N;
R1 is (C3.7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H2NC(0)-, or (Q.
3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci_3)alkoxy, all optionally substituted with one or more halogens or;
R1 is (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, or (Ci-3)alkoxycarbonyl, (di)(Ci_ 6)alkylaminocarbonyl, (Ci.4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogens or;
R1 is (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, or (Ci-3)alkoxycarbonyl, (di)(Ci_
6)alkylaminocarbonyl, (Ci-4)alkyl or (Ci-3)alkoxy, all optionally substituted with one or more halogens;
R2 is C(0)OH, 5-tetrazoylyl, or HOC(CF3)2;
R3 is independently selected from hydrogen, halogen, cyano, nitro or (Ci-4)alkyl, optionally substituted with one or more halogens; and
R4-R7 independently are H, halogen, amino, cyano, hydroxy, (Ci-3)alkoxy, (Ci-4)alkyl, optionally substituted with one or more halogens.
The compound of claim 1, wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; and (iii) CR4, N, CR6, CR7.
The compound of claim 3, wherein A4, A5, A6, A7 is (i) CR4, CR5, CR6, CR7, or (ii) N, CR5, CR6, CR7; and Y is N.
The compound of claim 4, wherein
X is C(O) or S02;
R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from (Ci-4)alkyl or halogen; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (Ci-4)alkyl; or (iii) (C6-i4)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy,
Figure imgf000135_0001
(Ci-4)alkyl, (Ci_3)alkoxy, wherein (Ci.3)alkoxycarbonyl, (Ci.4)alkyl and (Ci.3)alkoxy are optionally substituted with one or more halogens.
6. The compound of claim 5, wherein
R1 is (C2-9)heteroaryl or (C6-i4)aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy,
Figure imgf000135_0002
(Ci_ 4)alkyl or
Figure imgf000135_0003
(Ci-4)alkyl and (Ci.3)alkoxy are optionally substituted with one or more halogens.
7. The compound of claim 6, wherein R1 is phenyl, naphthyl, pyridinyl, quinolinyl,
benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy,
Figure imgf000135_0004
(Ci-4)alkyl or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (Ci-4)alkyl and (Ci-3)alkoxy are optionally substituted with one or more halogens.
8. The compound of claim 7, wherein R1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (Ci_ 4)alkyl or
Figure imgf000135_0005
(Ci-4) are optionally substituted with one or more halogens.
9. The compound of claim 8, wherein R2 is C(0)OH.
10. The compound of claim 3 having Formula lb
Figure imgf000135_0006
lb and a pharmaceutically acceptable salt or solvate thereof.
11. The compound of claim 10 having Formula Ic
Figure imgf000136_0001
Ic or a pharmaceutically acceptable salt or solvate thereof wherein,
X is C(O) or S02
R is selected from halogen, amino, cyano, nitro, hydroxy, H2NC(0)-, (Ci_
3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl,
Figure imgf000136_0002
or (Ci-3)alkoxy, wherein (Ci-3)alkoxycarbonyl, (di)(Ci-6)alkylaminocarbonyl, (Ci_4)alkyl or (Ci-3)alkoxy are optionally substituted with one or more halogens; and
x is 0, 1, 2, 3, 4 or 5.
12. The compound of claim 11 having Formula Id
Figure imgf000137_0001
Id
and a pharmaceutically acceptable salt or solvate thereof.
The compound of claim 12 having Formula Ie
Figure imgf000137_0002
Ie
and a pharmaceutically acceptable salt or solvate thereof. A compound according to claim 1 selected from: -( 1 -(2,6-dichlorobenzoyl)- 1 H-indazol-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-5-fluoro-lH-indazol-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-7-fluoro-lH-indazol-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-4-fluoro-lH-indazol-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-6-fluoro-lH-indazol-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
4-(l-(2-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid; 4-(l-(2,6-dichlorobenzoyl)-lH-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid;
4-(l-(2,6-dichlorobenzoyl)-lH-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
1,1, 1,3,3, 3-hexafluoro-2-(4-(l-(2-(trifluoromethyl)phenylsulfonyl)-lH-indazol-3- yl)phenyl)propan-2-ol;
Figure imgf000138_0001
4-(l-(2,3,4-trichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
4-( 1 -(2-cyanophenylsulfonyl)- 1 H-indazol-3 -yl)benzoic acid;
4-(l-(2-(trifluoromethoxy)phenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
4-(l -(naphthalen- 1 -ylsulfonyl)- 1 H-indazol-3 -yl)benzoic acid;
4-(l-(2,6-dichlorophenylsulfonyl)-lH-indazol-3-yl)benzoic acid;
4-(l-(benzo[c][l,2,5]oxadiazol-4-ylsulfonyl)-lH-indazol-3-yl)benzoic acid;
4-(l-(2-cyano-5-methylphenylsulfonyl)-l H-indazol-3 -yl)benzoic acid;
4-(l -(3, 5 -dimethylphenylsulfonyl)-l H-indazol-3 -yl)-3-fluorobenzoic acid;
4-(l -(3, 5 -dimethylphenylsulfonyl)-l H-indazol-3 -yl)-2-(trifluoromethyl)benzoic acid;
4-(l-(2-chlorophenylsulfonyl)-lH-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
3- (4-(lH-tetrazol-5-yl)phenyl)-l-(3-chlorophenylsulfonyl)-lH-indazole;
methyl 3-(3-(4-(lH-tetrazol-5-yl)phenyl)-lH-indazol-l-ylsulfonyl)thiophene-2- carboxylate;
3 -(4-( 1 H-tetrazol-5 -yl)phenyl)- 1 -(2-bromo-4-fluorophenylsulfonyl)- 1 H-indazole; 3 -(4-( 1 H-tetrazol-5 -yl)phenyl)- 1 -(3 -bromo-5 -chlorothiophen-2-ylsulfonyl)- 1 H- indazole;
4- (3-(4-(l H-tetrazol-5 -yl)phenyl)- 1 H-indazol- 1 -ylsulfonyl)-3 ,5 -dimethy lisoxazole; (3-(4-(lH-tetrazol-5-yl)phenyl)-lH-indazol-l-yl)(2,6-dichlorophenyl)methanone; (3-(4-(lH-tetrazol-5-yl)phenyl)-lH-indazol-l-yl)(2,3-dichlorophenyl)methanone; methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-1 H-indazol-3 -yl)-3- fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH- indazol-3-yl)-3-fluorobenzoic acid;
Sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-1 H-indazol-3 -yl)-3- fluorobenzoate;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- indazol-3-yl)benzoate;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)- 1 H-indazol-3 - yl)benzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- indazol-3-yl)benzoate;
methyl 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- pyrazolo[4,3-b]pyridin-3-yl)-3- fluorobenzoate;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH- pyrazolo[4,3-b]pyridin-3-yl)-3- fluorobenzoate; (2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-(4-(l ,1 , 1 ,3,3,3-hexafluoro-2- hydroxypropan-2-yl)phenyl)- 1 H-indazol- 1 -yl)methanone;
3- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzoic acid; 2-(3-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)phenyl)acetic acid;
2-(4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)phenyl)acetic acid;
2-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzoic acid;
Sodium 3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3- yl)benzoate;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)benzamide; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-fluoro-5- methylbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3- methylbenzoicacid;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1 H-indazol-3 -yl)-2- methoxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-2-fluorobenzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-2- fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-2-methylbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-3- methoxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,6- difluorobenzoic acid;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1 H-indazol-3 -yl)-2- isopropylbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-3, 5- dimethoxybenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2-cyano benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,3- difluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2,5- difluorobenzoic acid;
2- chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5- fluorobenzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5-fluoro-2- methoxybenzoic acid;
5- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-2- hydroxybenzoic acid;
3- fluoro-4-(4-fluoro-l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
4- (4-fluoro-l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
3- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl) benzoic acid;
2- (4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)
phenyl)acetic acid;
(2-chloro-6-(trifluoromethyl)phenyl)(3-(4-(l , 1 ,1 ,3,3,3-hexafluoro-2-hydroxypropan-2- yl)phenyl)-lH-pyrazolo[4,3-b]pyridin-l-yl)methanone;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-3- methylbenzoic acid;
3- chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3- yl)benzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- methoxybenzoic acid;
2-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-5- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2,5- difluorobenzoic acid; 5-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- hydroxybenzoic acid;
4-(l-(2-fluoro-6-methoxybenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
3- fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
4- (l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-(trifluoromethyl)-lH-indazol-3 -yljbenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-2-isopropylbenzoic acid; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-2-fluoro benzoate; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-3-fluoro benzoate; 3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)benzoic acid;
3- fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
sodium 3-fluoro-4-(l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoate;
4- (7-fluoro- 1 -(2-fluoro-6-methoxybenzoyl)- 1 H-indazol-3-yl)benzoic acid;
3- fluoro-4-(7-fluoro-l-(2-fluoro-6-methoxybenzoyl)-lH-indazol-3-yl)benzoic acid;
4- (6-bromo-l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl) benzoic acid;
4-(6-bromo-l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-methoxy-lH-indazol-3-yl)
benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl)benzoic acid; sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl)
benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-lH-indazol-3- yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-lH-indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(methoxymethyl)-lH-indazol-3- yl)benzoic acid;
l-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-lH-indazole- 6-carboxylic acid;
methyl 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2- hydroxyethylcarbamoyl)- 1 H- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)- lH-indazol-
3-yl)benzoic acid;
sodium 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6- (2-hydroxyethylcarbamoyl)- 1 H- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3- yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol- 3-yl)benzoic acid;
sodium 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2 -hydroxyethylcarbamoyl)- 1 H- indazol-3-yl)benzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-3 fluorobenzoic acid;
sodium 4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)- 1 H-indazol
3-yl)-3-fluorobenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol-
3-yl)-2-fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH-indazol-
3 -yl)-3 -fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-2 fluorobenzoic acid;
3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH- indazol-3-yl)benzoic acid;
3-chloro-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-lH- indazol-3-yl)benzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-lH-indazol- 3-yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-lH-indazol-
3-yl)-3-fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-methoxypropylcarbamoyl)-lH-indazol-
3-yl)-3-fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxypropylcarbamoyl)-lH-indazol-
3-yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(4-hydroxybutylcarbamoyl)-lH-indazol- 3-yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-
1 H-indazol-3 -yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-
1 H-indazol-3 -yl)-3-fluorobenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-methoxyethyl)(methyl)carbamoyl)-
1 H-indazol-3 -yl)-3-fluorobenzoic acid;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-fluoroazetidine- 1 -carbonyl)- 1 H- indazol-3-yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3,3-difluoroazetidine-l -carbonyl)- 1H- indazol-3-yl)benzoic acid;
4-(l -(2-chloro-6-(trifluoromethyl)benzoyl)-6-(pyrrolidine- 1 -carbonyl)- 1 H-indazol-3 - yl)benzoic acid;
4-(6-(azetidine- 1 -carbonyl)- 1 -(2-chloro-6-(trifluoromethyl)benzoyl)- 1 H-indazol-3- yl)benzoic acid;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1 H- indazol-3-yl)-2- hydroxybenzoic acid;
2-acetoxy-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-1 H-indazol-3 - yl)benzoic acid;
sodium 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)- 4-fluoro-l H-indazol-3 -yl)-2- hydroxybenzoate;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-l H-indazol-3 -yl)-2-fluoro-6- hydroxybenzoic acid; 4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-5-fluoro-2- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-lH-indazol-3-yl)-3,6-difluoro-2- hydroxybenzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3-yl)-2- hydroxybenzoic acid;
2-acetoxy-4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-pyrazolo[4,3-b]pyridin-3- yl)benzoic acid;
4-(l-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-lH-indazol-3-yl)-2- hydroxybenzoic acid;
4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl) benzoyl)- lH-indazol-3-yl)benzoic acid;
4-(6-(aminomethyl)-l-(2-chloro-6-(trifluoromethyl)benzoyl)-lH-indazol-3-yl)-3- fluorobenzoic acid;
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)- 1 H-indazol-3 -yl)-2-(difluoro
methyl)benzoic acid; and
4-( 1 -(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano- 1 H- indazol-3 -yl)benzoic acid.
15. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients.
16. The pharmaceutical composition of claim 15, which further comprises at least one
additional therapeutically active agent.
17. Use of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a disease or condition mediated by Retinoic acid receptor-related Orphan Receptor gamma t (RORgammaT).
18. A method for treating a disease or condition mediated by RORgammaT in a subject comprising administering to the subject an amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, that is effective for treating the disease or condition mediated by RORgammaT in the subject.
19. The method of claim 18, wherein the disease or condition is an autoimmune disease or inflammatory disease.
The method of claim 19, wherein the disease or condition is multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
PCT/CN2012/071017 2011-02-11 2012-02-10 Rorgammat inhibitors WO2012106995A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US13/983,818 US9095583B2 (en) 2011-02-11 2012-02-10 RORgammaT inhibitors
EP12744370.3A EP2683693B1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
JP2013552823A JP5934721B2 (en) 2011-02-11 2012-02-10 RORγT inhibitor
CN201280018025.3A CN103748076A (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
KR1020137023663A KR20140044791A (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
AU2012214029A AU2012214029A1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
MX2013009149A MX2013009149A (en) 2011-02-11 2012-02-10 Rorgammat inhibitors.
BR112013020352A BR112013020352A2 (en) 2011-02-11 2012-02-10 compound, pharmaceutical composition, use of a compound and method for treating median rorgamat disease or condition in an individual
CA2828059A CA2828059A1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
RU2013141528/04A RU2013141528A (en) 2011-02-11 2012-02-10 RORGAMMAT RECEPTOR INHIBITORS
US14/752,195 US9603838B2 (en) 2011-02-11 2015-06-26 RORgammaT inhibitors
US15/463,371 US9884043B2 (en) 2011-02-11 2017-03-20 RORgammaT inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11154188A EP2487159A1 (en) 2011-02-11 2011-02-11 RorgammaT inhibitors
EP11154188.4 2011-02-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/983,818 A-371-Of-International US9095583B2 (en) 2011-02-11 2012-02-10 RORgammaT inhibitors
US14/752,195 Division US9603838B2 (en) 2011-02-11 2015-06-26 RORgammaT inhibitors

Publications (1)

Publication Number Publication Date
WO2012106995A1 true WO2012106995A1 (en) 2012-08-16

Family

ID=43901458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/071017 WO2012106995A1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors

Country Status (11)

Country Link
US (3) US9095583B2 (en)
EP (2) EP2487159A1 (en)
JP (1) JP5934721B2 (en)
KR (1) KR20140044791A (en)
CN (1) CN103748076A (en)
AU (1) AU2012214029A1 (en)
BR (1) BR112013020352A2 (en)
CA (1) CA2828059A1 (en)
MX (1) MX2013009149A (en)
RU (1) RU2013141528A (en)
WO (1) WO2012106995A1 (en)

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013178362A1 (en) 2012-05-31 2013-12-05 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
WO2014023367A1 (en) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma
WO2014026327A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014028597A3 (en) * 2012-08-15 2014-05-01 Merck Sharp & Dohme Corp. 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015035032A1 (en) * 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP2015516428A (en) * 2012-05-08 2015-06-11 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Tetrahydro [1,8] naphthyridinesulfonamide and related compounds for use as agonists of RORγ and for the treatment of diseases
WO2015087234A1 (en) * 2013-12-10 2015-06-18 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl indole analogues useful as ror gamma modulators
WO2015096771A1 (en) * 2013-12-25 2015-07-02 中国科学院广州生物医药与健康研究院 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide compound and composition and use thereof
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2015523329A (en) * 2012-05-08 2015-08-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Tetrahydronaphthyridine and related bicyclic compounds for inhibiting RORγ activity and treating diseases
WO2015139621A1 (en) * 2014-03-18 2015-09-24 北京韩美药品有限公司 4-heteroaryl substituted benzoic acid or benzamides compound
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9296763B2 (en) 2010-08-10 2016-03-29 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016063080A1 (en) * 2014-10-24 2016-04-28 Orca Pharmaceuticals Limited Indazole and indole derivatives as inhibitors of retinoic acid relates orphan receptor gamma (ror gamma) for the treatment of immune-related diseases
US20160159791A1 (en) * 2013-07-30 2016-06-09 Brian Nicholas Cook Compounds as modulators of rorc
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016130818A1 (en) * 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2016145298A1 (en) 2015-03-12 2016-09-15 The Regents Of The University Of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP2016534139A (en) * 2013-09-11 2016-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Keto-imidazopyridine derivatives as RORc modulators
JP2016534994A (en) * 2013-10-15 2016-11-10 ヤンセン ファーマシューティカ エヌ．ベー． RORγT secondary alcohol quinolinyl modulator
WO2016198908A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
WO2016200851A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9556168B2 (en) 2012-08-15 2017-01-31 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9603838B2 (en) 2011-02-11 2017-03-28 Merck Sharp & Dohme Corp. RORgammaT inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2017075185A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075178A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2017075182A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663522B2 (en) 2012-08-15 2017-05-30 Merck Sharp & Dohme Corp. 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors
US10201546B2 (en) 2013-10-15 2019-02-12 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US20190062328A1 (en) * 2016-01-21 2019-02-28 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10369146B2 (en) 2013-10-15 2019-08-06 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10618918B2 (en) 2015-03-17 2020-04-14 Qpex Biopharma, Inc. Substituted boronic acids as antimicrobials
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057421B1 (en) * 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
CN106132422A (en) 2014-02-27 2016-11-16 莱斯拉公司 Use the adoptive cellular therapy ＆ related methods for the treatment of of the agonist of retinoic acid receptors related orphan receptor y
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
WO2016201225A1 (en) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
NZ741112A (en) * 2015-09-21 2021-07-30 Plexxikon Inc Heterocyclic compounds and uses thereof
CN105412929B (en) * 2015-11-27 2018-03-20 肖定璋 Applications of the UTR of IL7R 3 ' in regulation and control retinoic acid-related orphan nuclear receptor expression
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
WO2018084120A1 (en) * 2016-11-01 2018-05-11 学校法人東京理科大学 Benzoic acid derivative and dehydration-condensation agent, and methods for producing ester and lactone
JP2020111510A (en) * 2017-03-29 2020-07-27 科研製薬株式会社 Indazole derivative and medicament containing the same
AU2018252099B2 (en) 2017-04-11 2021-08-12 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
SG11201911634WA (en) * 2017-06-12 2020-01-30 Cypress Bio Tech Company Ltd Multi-application insect repellent additive
CN109485595B (en) * 2017-09-12 2022-05-27 江苏恒瑞医药股份有限公司 Hydrophilic group substituted indole formamide derivative, preparation method and medical application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429257A2 (en) * 1989-11-17 1991-05-29 Glaxo Group Limited Indole derivatives
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
JP2007238463A (en) * 2006-03-06 2007-09-20 Nippon Menaade Keshohin Kk Ror activation agent
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
GB0117577D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP2295429A1 (en) 2004-08-03 2011-03-16 Wyeth LLC 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases
CA2583428A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
SE0402762D0 (en) 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
CN100516049C (en) 2004-11-16 2009-07-22 永信药品工业股份有限公司 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as anti-angiogenic agents
MX2008010481A (en) 2006-02-17 2008-12-19 Memory Pharm Corp Compounds having 5-ht6 receptor affinity.
BRPI0708615A2 (en) 2006-03-07 2011-06-07 Array Biopharma Inc heterobicyclic pyrazole compounds and methods of use
MX2008015638A (en) * 2006-06-09 2009-01-09 Icos Corp Substituted phenyl acetic acids as dp-2 antagonists.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US7981888B2 (en) 2007-04-16 2011-07-19 Abbott Laboratories 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
AR067326A1 (en) 2007-05-11 2009-10-07 Novartis Ag IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
MX2009013333A (en) 2007-06-05 2010-01-18 Schering Corp Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer.
WO2009015067A2 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
FR2933609B1 (en) * 2008-07-10 2010-08-27 Fournier Lab Sa USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE TREATMENT OF PARKINSON'S DISEASE.
CN102264743B (en) * 2008-11-25 2015-02-11 罗彻斯特大学 MLK inhibitors and methods of use
WO2010150837A1 (en) * 2009-06-25 2010-12-29 第一三共株式会社 Indoline derivative
EP2459184A1 (en) * 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
JP2013514385A (en) 2009-12-18 2013-04-25 ヤンセン ファーマシューティカ エヌ．ベー． Substituted aminothiazolone indazoles as estrogen-related receptor alpha modulators
EP2536275A1 (en) 2010-02-16 2012-12-26 UWM Research Foundation, Inc. Methods of reducing virulence in bacteria
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
JP6063870B2 (en) 2010-11-08 2017-01-18 ライセラ・コーポレイション Treatment of N-sulfonylated tetrahydroquinolines and related bicyclic compounds and diseases for inhibition of RORγ activity
KR20120063283A (en) 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
JP6157358B2 (en) * 2010-12-22 2017-07-05 ルートヴィヒ‐マクシミリアン‐ユニバーシタット ミュンヘン Organozinc complexes and methods for making and using organozinc complexes
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP2014166961A (en) 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd Novel indazole derivative
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429257A2 (en) * 1989-11-17 1991-05-29 Glaxo Group Limited Indole derivatives
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
JP2007238463A (en) * 2006-03-06 2007-09-20 Nippon Menaade Keshohin Kk Ror activation agent
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YONGJUN WANG ET AL.: "Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORalpha and RORgamma", ACS CHEMICAL BIOLOGY, vol. 5, no. 11, 2010, pages 1029 - 1034, XP002635148 *
YONGJUN WANG ET AL.: "Modulation of Retinoic Acid Receptor-related Orphan Receptor alpha and gamma Activity by 7-Oxygenated Sterol Ligands", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 7, 12 February 2010 (2010-02-12), pages 5013 - 5025, XP055084028 *

Cited By (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183034B2 (en) 2010-08-10 2019-01-22 Rempex Pharmaceuticals, Inc. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10172874B2 (en) 2010-08-10 2019-01-08 Rempex Pharmaceuticals, Inc. Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US9296763B2 (en) 2010-08-10 2016-03-29 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US11684629B2 (en) 2010-08-10 2023-06-27 Melinta Subsidiary Corp. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US9694025B2 (en) 2010-08-10 2017-07-04 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10004758B2 (en) 2010-08-10 2018-06-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and methods of making the same
US10639318B2 (en) 2010-08-10 2020-05-05 Rempex Pharmaceuticals, Inc. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US11090319B2 (en) 2010-08-10 2021-08-17 Melinta Subsidiary Corp. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9603838B2 (en) 2011-02-11 2017-03-28 Merck Sharp & Dohme Corp. RORgammaT inhibitors
US9884043B2 (en) 2011-02-11 2018-02-06 Merck Sharp & Dohme Corp. RORgammaT inhibitors
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
JP2015516428A (en) * 2012-05-08 2015-06-11 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Tetrahydro [1,8] naphthyridinesulfonamide and related compounds for use as agonists of RORγ and for the treatment of diseases
JP2015523329A (en) * 2012-05-08 2015-08-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Tetrahydronaphthyridine and related bicyclic compounds for inhibiting RORγ activity and treating diseases
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10301272B2 (en) 2012-05-31 2019-05-28 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
WO2013178362A1 (en) 2012-05-31 2013-12-05 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US11007206B2 (en) 2012-06-06 2021-05-18 Melinta Subsidiary Corp. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9458104B2 (en) 2012-08-09 2016-10-04 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ
EP3118189A1 (en) 2012-08-09 2017-01-18 Phenex Pharmaceuticals AG Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma
WO2014023367A1 (en) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014028597A3 (en) * 2012-08-15 2014-05-01 Merck Sharp & Dohme Corp. 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
US9556168B2 (en) 2012-08-15 2017-01-31 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof
US9487490B2 (en) 2012-08-15 2016-11-08 Merck Sharp & Dohme Corp. 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof
US9663522B2 (en) 2012-08-15 2017-05-30 Merck Sharp & Dohme Corp. 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof
US10196354B2 (en) 2012-08-15 2019-02-05 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
US9745265B2 (en) 2012-08-15 2017-08-29 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
WO2014028589A3 (en) * 2012-08-15 2014-05-08 Merck Sharp & Dohme Corp. 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US9745297B2 (en) * 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
US20160159791A1 (en) * 2013-07-30 2016-06-09 Brian Nicholas Cook Compounds as modulators of rorc
US9745267B2 (en) 2013-09-05 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
WO2015035032A1 (en) * 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
JP2016530297A (en) * 2013-09-05 2016-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bicyclic compounds as modulators of ROR gamma
JP2016534139A (en) * 2013-09-11 2016-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Keto-imidazopyridine derivatives as RORc modulators
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10369146B2 (en) 2013-10-15 2019-08-06 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
JP2016534994A (en) * 2013-10-15 2016-11-10 ヤンセン ファーマシューティカ エヌ．ベー． RORγT secondary alcohol quinolinyl modulator
US10201546B2 (en) 2013-10-15 2019-02-12 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
EA029489B1 (en) * 2013-12-10 2018-04-30 Гленмарк Фармасьютикалс С.А. Bicyclic heteroaryl indole analogues useful as ror gamma modulators
US9682977B2 (en) 2013-12-10 2017-06-20 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl indole analogues useful as ROR gamma modulators
WO2015087234A1 (en) * 2013-12-10 2015-06-18 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl indole analogues useful as ror gamma modulators
JP2016539989A (en) * 2013-12-10 2016-12-22 グレンマーク・ファーマシューティカルズ・エスエー Bicyclic heteroarylindole congeners useful as ROR gamma modulators
CN105980364A (en) * 2013-12-10 2016-09-28 格兰马克药品股份有限公司 Bicyclic heteroaryl indole analogues useful as ror gamma modulators
WO2015096771A1 (en) * 2013-12-25 2015-07-02 中国科学院广州生物医药与健康研究院 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide compound and composition and use thereof
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP2017505318A (en) * 2014-02-03 2017-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Dihydropyrrolopyridine inhibitors of ROR gamma
US10047085B2 (en) 2014-02-03 2018-08-14 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9624217B2 (en) 2014-02-03 2017-04-18 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2015139621A1 (en) * 2014-03-18 2015-09-24 北京韩美药品有限公司 4-heteroaryl substituted benzoic acid or benzamides compound
US10669292B2 (en) 2014-05-05 2020-06-02 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10087184B2 (en) 2014-10-14 2018-10-02 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of RORγ
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016063080A1 (en) * 2014-10-24 2016-04-28 Orca Pharmaceuticals Limited Indazole and indole derivatives as inhibitors of retinoic acid relates orphan receptor gamma (ror gamma) for the treatment of immune-related diseases
WO2016063081A1 (en) * 2014-10-24 2016-04-28 Orca Pharmaceuticals Limited Indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ror gamma) for the treatment of immune-related diseases
US9522134B2 (en) 2014-10-24 2016-12-20 Orca Pharmaceuticals Limited Compounds
US10383850B2 (en) 2014-10-24 2019-08-20 Orca Pharmaceuticals Limited Indazole and indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ROR gamma) for the treatment of immune-related diseases
US9861612B2 (en) 2014-10-24 2018-01-09 Orca Pharmaceuticals Limited Indolyl-containing RORγt inhibitors
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016130818A1 (en) * 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10959984B2 (en) 2015-03-12 2021-03-30 The Regents Of The University Of California Methods for treating cancer with RORγ inhibitors
WO2016145298A1 (en) 2015-03-12 2016-09-15 The Regents Of The University Of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
US10618918B2 (en) 2015-03-17 2020-04-14 Qpex Biopharma, Inc. Substituted boronic acids as antimicrobials
US10106501B2 (en) 2015-06-09 2018-10-23 Abbvie Inc. Nuclear receptor modulators
WO2016200851A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
RU2715897C2 (en) * 2015-06-09 2020-03-04 Эббви Инк. Modulators of nuclear receptors
WO2016198908A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
EP3368535A4 (en) * 2015-10-27 2019-06-19 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CN108431009A (en) * 2015-10-27 2018-08-21 默沙东公司 Substituted indazole compound and application thereof as ROR γ T inhibitor
US10689369B2 (en) 2015-10-27 2020-06-23 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
WO2017075178A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US20190194186A1 (en) * 2015-10-27 2019-06-27 Merck Sharp & Dohme Corp. HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2017075182A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017075185A1 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11453644B1 (en) 2015-12-15 2022-09-27 Astrazeneca, Ab Compounds
US10526286B2 (en) 2015-12-15 2020-01-07 Astrazeneca Ab Compounds
US10988445B2 (en) 2015-12-15 2021-04-27 Astrazeneca Ab Compounds
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
US10662187B2 (en) * 2016-01-21 2020-05-26 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
US20190062328A1 (en) * 2016-01-21 2019-02-28 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11180512B2 (en) 2016-06-30 2021-11-23 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US11999759B2 (en) 2016-06-30 2024-06-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10570159B2 (en) 2016-06-30 2020-02-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors
US11351178B2 (en) 2017-04-14 2022-06-07 Italfarmaco Spa Selective HDAC6 inhibitors
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US12024517B2 (en) 2018-05-04 2024-07-02 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Also Published As

Publication number Publication date
US9884043B2 (en) 2018-02-06
EP2683693B1 (en) 2017-04-05
JP5934721B2 (en) 2016-06-15
US9095583B2 (en) 2015-08-04
MX2013009149A (en) 2014-02-17
AU2012214029A8 (en) 2013-10-17
EP2683693A4 (en) 2014-10-08
BR112013020352A2 (en) 2017-08-08
US20170340610A1 (en) 2017-11-30
EP2683693A1 (en) 2014-01-15
US20140038942A1 (en) 2014-02-06
AU2012214029A1 (en) 2013-08-29
EP2487159A1 (en) 2012-08-15
CA2828059A1 (en) 2012-08-16
CN103748076A (en) 2014-04-23
KR20140044791A (en) 2014-04-15
JP2014509316A (en) 2014-04-17
US9603838B2 (en) 2017-03-28
RU2013141528A (en) 2015-03-20
US20150297566A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US9884043B2 (en) RORgammaT inhibitors
US10196354B2 (en) 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
EP2884976B1 (en) 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP2884977B1 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP2920149B1 (en) 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744370

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013552823

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2828059

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/009149

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012214029

Country of ref document: AU

Date of ref document: 20120210

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137023663

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012744370

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012744370

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013141528

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13983818

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013020352

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013020352

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130809